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Chemotherapy has a long history in cancer treatment, and the anthracycline used in 
Paper I and II are among the most effective anti-cancer drugs developed. 
Unfortunately, the use of anthracyclines is dose-restricted due to the risk of 
cumulative toxicity in healthy tissue, most notably in the heart. Targeted therapy 
using all-trans retinoic acid (ATRA) is used to differentiate, and hence, eliminate 
acute promyelocytic leukemia (APL) cells, and is combined with low dose 
anthracyclines to remove live or ATRA resistant cells. Recently, cAMP was 
recommended as adjuvant to standard APL therapy since it enhances ATRA induced 
differentiation of APL cells. In Paper I we demonstrate that cAMP in fact abrogate 
the anti-cancer effect of the anthracycline Daunorubicine (DNR) in blasts from APL 
patients and also in ATRA-sensitive and insensitive APL cell lines. The protection 
was dependent on the cytoplasmic PKA-type I rather than perinuclear PKA type-II, 
and was associated with (inactivating) phosphorylation of pro-apoptotic Bad and 
(activating) phosphorylation of the acute myeloid leukemia (AML) oncogene cAMP-
responsive element binding protein (CREB). Mice with orthotopic NB4 cell leukemia 
showed a more rapid disease progression when given cAMP-increasing agents 
(prostaglandin E2 analog and aminophylline), both with and without DNR 
chemotherapy. Together this suggests that the beneficial pro-differentiating and non-
beneficial pro-survival APL cell effects of cAMP should be weighed against each 
other. Although the mechanism behind anthracycline mediated cardiotoxicity is 
highly contested, intramyocardial production of reactive oxygen species (ROS) is 
generally accepted as a strong candidate, and has increased the focus on antioxidants 
in cardioprotective strategies. In Paper II, we demonstrate that Red Palm Oil (RPO) 
supplemented diet during chemotherapy attenuate cardiotoxic side-effects of 
daunorubicin, by improving aortic output and coronary flow in the isolated working 
rat heart model. Improved hemodynamic was accompanied by stabilization of 
important antioxidant systems (SOD1 and NOS1) and reduction of stress-induced 
MAPK activation.  
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While cancer is a consequence of restricted cell death, the opposite scenario, with 
increased cell death is an important component of ischemia-reperfusion induced 
injury. Since prolonged ischemia may lead to cardiac cell death, rapid and adequate 
reperfusion is a necessity to salvage the compromised cardiac tissue. Paradoxically, 
reperfusion per se also induces cell death (lethal reperfusion injury) a process 
involving opening of the mitochondrial permeability transition pore (mPTP). 
Different ways to limit or delay cardiomyocyte cell death have emerged in the 
laboratory setting, and are evaluated as clinical candidates to further improve the 
outcome of patients with acute myocardial infarction (AMI). In paper III and IV we 
utilize the Langendorff perfusion setup for the ex vivo rat heart, to evaluate different 
therapeutic strategies to reduce ischemia-reperfusion induced injury. In Paper III we 
show that corticotropin releasing factor (CRF) significantly reduce infarct size when 
applied to the heart prior to a lethal ischemic insult, and was cytoprotective in 
neonatal mouse cardiomyocytes when added prior to a lethal simulated ischemic 
event (hypoxia). CRF was however not protective when administered at the point of 
ischemic reperfusion or hypoxic reoxygenation. The cardioprotective effects of CRF 
was mediated via activation of PKA and PKC dependent signaling pathways 
downstream of CRF receptor type 2 (CRFR2). In Paper IV we evaluated the possible 
additive effects of combining known cardioprotective treatments. We found that 
combining insulin reperfusion therapy with direct Glycogen synthase kinase 3 β 
(GSKβ) inhibition at reperfusion did not confer any additive effect, but showed 
similar cardioprotection as seen when the treatments were administered separately. 
Surprisingly, we found that combining either of the two pharmacologic interventions 
with ischemic postconditioning (IPost) abrogated all cardioprotective effect. This loss 
of cardioprotection was accompanied with blunted Akt phosphorylation. To our 
knowledge, we are the first to demonstrate the loss of protection when combining two 
otherwise cardioprotective regimes.  
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ACD  autophagic cell death 
AKAP A-kinase anchoring protein 
Akt/PKB Protein Kinase B 
AML  acute myeloid leukemia 
APL  acute promyelocytic leukemia 
ATO  arsenic trioxide 
ATRA all-trans retinoic acid 
Bcl-2/XL B-cell lymphoma 2/extra large 
BH domain Bcl-2 homology domain 
cAMP  3'-5'-cyclic adenosine monophosphate 
cNMP  cyclic nucleotide monophosphate 
CHF  congestive heart failure 
CREB  cAMP-responsive element binding protein 
CRF  corticotropin releasing factor 
CRFR  corticotropin receptor 
CVD  cardiovascular disease 
CR  complete remission 
DFS  disease-free survival 
DISC  death inducing signaling complex 
DNA  deoxyribonucleic acid  
DNR  daunorubicin 
DOX  doxorubicine 
eNOS  endothelial nitrogenoxide synthase 
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Epac  exchange proteins directly activated by cAMP 
ERK  extracellular signal-regulated kinase 
GEF  guanine nucleotide exchange factor 
GIK  glucose-insulin-kalium(potassium) 
GSK3  glycogen synthase kinase 3 
GTP  guanosine-5'-triphosphate 
IDA  idarubicin 
IL-6  interleukin-6 
INSR  insulin receptor 
IC  ischemic conditioning 
IPC  ischemic preconditioning 
IPost  ischemic postconditioning 
JAK  janus kinase 
KHB  krebs-henseleit buffer 
MAPK mitogen-activated protein kinases 
Mcl-1  induced myeloid leukemia cell differentiation protein 
MEK  mitogen-activated protein kinase kinase 
mPTP  mitochondrial permeability transition pore 
NADH nicotinamide adenine dinucleotide 
NB4-RAr  NB4-retinoic acid resistant 
NO  nitrogen oxide 
PCD  programmed cell death 
PCI  percutaneous coronary intervention 
PDE  phosphodiesterase 
PI3K  phosphatidylinositide 3-kinases 
PKA  protein kinase A 
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PKC  protein kinase C 
PKG  protein kinase G 
PML  promyelocytic leukemia protein 
RA  retinoic acid 
RAR  retinoic acid receptor  
RAS  retinoic acid syndrome 
RISK  reperfusion injury salvage kinase 
ROS  reactive oxygen species 
RPO  red palm oil 
RTK  receptor tyrosine kinase 
SAFE  survivor activating factor enhancement 
SOD  superoxide dismutase 
STAT  signal transducer and activator of transcription 
TNF-α tumor necrosis factor- α 





This thesis represents basic research devoted to reduce the harmful consequence of 
myocardial ischemia, and also modulate classical anti-cancer therapy to alleviate drug 
associated toxicity. I have focused on modulation of cell death in the two different 
pathologic situations represented by ischemia-reperfusion induced injury and 
anthracycline induced apoptosis/cardiotoxicity. 
Cardiovascular diseases are the leading cause of death globally, estimated to 17.3 mill 
deaths in 2008, from where 42% were due to myocardial ischemia [1]. Myocardial 
ischemia is defined as “a condition in which the coronary blood flow is inadequate to 
permit the maintenance of a steady state metabolism” [2]. Therefore, rapid and 
adequate reperfusion of the compromised cardiac tissue is necessary, as prolonged 
ischemia will lead to cardiac cell death.  However, reperfusion itself induces cardiac 
injury, e.g. lethal reperfusion injury, contributing to the total infarct size and presents 
as an important target for additional cardioprotection. Although the precise 
mechanism needs to be fully elucidated, it is clear that cell death is the most 
important consequence of both ischemic as well as reperfusion induced injury. 
Contrary, attenuation of cell death is the key feature of cancer. Cancer is a 
heterogeneous group of diseases which are increasing both in incidence and 
mortality. Chemotherapy includes more than hundred different drugs used for cancer 
treatment, and the anthracyclines described and used in this thesis (daunorubicine-
DNR) has been among the most effective antitumor drugs ever developed. 
Unfortunately, due to the risk of cumulative cardiotoxicity the use of high dose 
anthracycline is hampered and may reduce its therapeutic potential. This thesis 
explores the possibility of, indirectly or directly, reducing the toxic side-effects of 
anthracycline treatment, by combining classical treatment with novel agents (Paper I 
and II) and also reducing ischemia-reperfusion induced cardiac injury using novel 
therapeutic strategies (Paper III and IV). 
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1.2 Cell death 
Precise description of  naturally occurring cell death was reported in more than 100 
papers as early as the 19th century (reviewed in [3]). However, the introduction of the 
term Programmed Cell Death (PCD) came in 1964 when Locksin and Williams 
realized that cell death occur at predicted time and places during development, and 
are programmed into the developmental plan of an organism [4]. Eight years later, 
Kerr, Wyllie and Currie further specialized the term by introducing apoptosis as a 
special variant of PCD. They described precise morphological features of apoptosis 
such as cell shrinkage and fragmentation, followed by phagocytosis of the apoptotic 
bodies. This process is highly distinguished from the pathological variant of cell 
death called necrosis (also called oncosis), where the cells tend to swell and rupture 
with subsequent inflammation [5] (Fig. 1.1). Necrosis has traditionally been 
considered as  an uncontrolled process, but accumulating evidence is now suggesting 
that necrosis can be finely regulated [6]. This process has been termed necroptosis 
and involves signaling via receptor-associated adaptor kinase RIP1 [7]. Finally, 
autophagy is also linked to PCD. Autophagy was described already in the 1960s, and 
is  a catabolic mechanism that involves degradation of damaged and dysfunctional 
cellular components through the lysosomal machinery [8]. The idea of autophagic 
cell death (ACD) gained its momentum in the 1990s with the discovery of the 
autophagy-related genes (ATG) [9] and the observation of caspase-independent cell 
death with non-apoptotic morphology [10]. However, ACD is only a morphological 
definition based on accumulation of autophagosomes in dying cells, and there is still 
an on-going debate whether ACD is actually cell death with autophagy rather than 
cell death by autophagy [11].  







Figure 1.1 Two important types of cell death are depicted. Necrosis involves cell swelling and 
rupture of the cell membrane, with release of intracellular components leading to inflammatory 
reactions. Apoptosis is an organized and controlled process with cell shrinkage and chromatin 
condensation, followed by formation of apoptotic bodies which are phagocytized by surrounding 
cells without induction of inflammation (figure from [12] ). 
 
1.2.1 Cell Death in “health and disease” 
In the adult organism, apoptosis is important for the clearance of damaged cells and is 
necessary for normal cell maintenance by acting as a counterbalance to cell 
proliferation [13]. In average, 50-70 billion cells undergo apoptosis every day in an 
adult organism [14]. Malfunction of the apoptotic signaling/machinery may have 
severe consequences as both too little and too much cell death result in pathological 
conditions. Neurodegenerative disorders such as Alzheimer’s and Parkinson’s, 
immunodeficiency syndrome (AIDS) and ischemia-reperfusion injury (myocardial 
infarction) are all associated with increased apoptosis. Ischemia-reperfusion induced 
injury is a result of both necrosis and apoptosis [15]. Whether apoptosis/necrosis 
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represents discriminate or more overlapping events leading to cell death is unclear, 
but it seems like necrosis is mainly found in the central part of the infarcted area, 
while apoptosis is more apparent at the border zone of the infarct [16]. In addition, 
recent reports indicate that apoptosis is accelerated by reperfusion [17-20]. Regarding 
autophagy, compelling evidence indicates up regulated levels of autophagy during 
ischemia-reperfusion [21, 22], however, the role of autophagy, whether being 
detrimental or beneficial to the ischemic myocardium, is a topic of growing interest 
and debate [23]. Contrary to ischemia-reperfusion injury, autoimmune disorders like 
Lupus, a variety of viral infections and last but not least, cancer, is associated with 
attenuation of apoptosis (for review see [24]). Evasion of apoptosis is actually one of 
the key components of malignant transformation [25],  and also an important 
mediator in the development of therapy resistance [26]. Therefore, detailed 
knowledge about the molecular mechanisms of both successful and failed treatments 
will facilitate an improved approach for anti-cancer treatment.  
1.2.2 Regulation of apoptosis 
Apoptosis is usually transmitted via two major signaling pathways (Fig.1.2). A 
variety of cellular stresses such as hypoxia and exposure to chemotherapeutic agents 
initiate the intrinsic pathway with release of several apoptosis related proteins from 
the mitochondrial inter-membrane space [27]. Released Cytochrome C, Apaf-1 and 
procaspase-9 oligomerize to form the “apoptosome” which activates caspase-3 and 
induce proteolysis of hundreds of proteins leading to apoptosis [28]. In the extrinsic 
pathway, cell-surface receptors connect death-promoting extracellular signals to 
apoptosis execution inside the cell. Ligand binding initiates assembly of the Death 
Inducing Signaling Complex (DISC), auto-activation of caspase-8 followed by 
caspase-3 activation and finally initiation apoptosis [29]. Another caspase-8 substrate 
is the BH3-only protein Bid. When activated, Bid translocate to the mitochondria, 
connecting the extrinsic pathway to the mitochondrial intrinsic pathway [30], and 
thereby amplifying the initial death receptor signal. The integrity of the mitochondrial 
membrane is regulated by the Bcl-2 family of proteins, which is divided into three 
groups. The anti-apoptotic proteins containing all four BH domains; Bcl-2, Bcl-XL, 
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Bcl-W and Mcl-1[31], the pro-apoptotic multi-BH domain proteins Bax, Bak and 
Bok [32] and the pro-apoptotic BH3-only proteins Bim, Bad, Bid, Puma and Noxa 
[33]. Members from the different groups may interact as homo- or heterodimers, and 
these interactions between pro and anti- apoptotic proteins act as checkpoints 




Figure 1.2 Apoptotic signaling induced via death receptor activation (extrinsic pathway) and stress-
induced stimuli (intrinsic pathway). Activation of death receptors leads to recruitment of specific 
adaptor proteins (FADD) and consequently recruitment and activation of pro-caspase 8. In the 
intrinsic pathway the mitochondria is perturbed in response to stress, which leads to release of 
proteins such as cytochrome c from the inter-mitochondrial membrane space. The release of 
mitochondrial proteins is regulated by anti-apoptotic proteins such as Bcl-2, Bcl-XL and Mcl-1 and 
pro-apoptotic proteins such as Bax, Bak and BH3-only proteins such as tBid and Bad. Once released, 
cytochrome c initiates the formation of the apoptosome complex and activation of the initiator 
caspase  9. Activated caspase 8 and  9 further activates the effector caspases 3,6 and 7 responsible for 




1.3 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is an aggressive hematological malignant disorder, 
characterized by accumulation of immature myeloid progenitor cells in the bone 
marrow and peripheral blood. The pathology is due to a block in differentiation in the 
early stage of hematopoiesis, combined with dysregulation of proliferation and 
apoptosis [35]. Since AML is a heterogeneous group of diseases the symptoms are 
diverse and nonspecific, but they are usually directly attributed to the leukemic 
infiltration of the bone marrow with concomitant cytopenia. Typical clinical signs are 
fatigue, hemorrhage,  infections and fever due to a decrease in platelets, red and white 
blood cells [36]. The major hypothesis of leukemogenesis is known as “the two hit 
model”, and was first presented by Gilliland in 2001. This hypothesis implies that 
two different mutations, in a transcription factor and a tyrosine kinase, will impair 
differentiation and confer survival and/or proliferative advantages, and are both 
necessary for AML development [37]. Acute promyelocytic leukemia (APL) is a 
subtype of AML, and accounts for more than 10% of all AML cases. It is 
characterized by accumulation of immature promyelocytes in the bone marrow and is 
highly associated with chromosomal translocation of the retinoic acid receptor alpha 
(RARα) on chromosome 17 [38]. RARs belongs to a family of nuclear hormone 
receptors which in complex with retinoic X receptor (RXR) acts as transcriptional 
repressors or activators [39]. In most chromosomal translocations (>98%), RARα is 
fused to the promyelocytic leukemia protein (PLM) gene on chromosome 15, 
resulting in the t(15;17) chromosomal translocation, generating the PML-RARα 
fusion protein. This fusion protein blocks differentiation by acting as a transcriptional 
repressor directly [40] or via recruitment of various partners [41, 42]. In addition, the 
fusion protein induces hypermethylation with silencing of genes necessary for 
promyelocytic differentiation [43, 44]. The prognosis of APL has changed 
dramatically the last three decades from being the worst subtype of AML to 
becoming the most favorable, all due to the first example of successful molecular 
targeted therapy. 
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1.3.1 The successes story of APL treatment 
Before the mid-80s, when chemotherapy was the sole agent in acute promyelocytic 
leukemia (APL) treatment, this malignancy was considered highly fatal with only 
40% 5-year disease free survival (DFS), despite a complete remission rate (CR) of 
80% [45]. However, in 1985 it was discovered that all-trans retinoic acid (ATRA) 
induce differentiation of immature promyelocytes to terminally differenced 
granulocytes, which eventually undergo apoptosis [40, 46]. This effect is attributed to 
the direct binding of ATRA to the ligand-binding site of the RARα moiety of the 
PML-RARα fusion protein, initiating the release of transcriptional co-repressors and 
recruitment of co-activators [45]. Although ATRA therapy alone had promising 
effect with CR up to 85%, prolonged ATRA treatment lead to ATRA resistance, early 
relapse and retinoic acid syndrome (RAS). An international effort to optimize the 
ATRA regime was initiated, and since the early 1990s  ATRA has been combined 
with conventional chemotherapy such as daunorubicine (DNR), resulting in  CR up to 
95% with 74% 5-year DFS [47]. During the 1990s one of the oldest drugs in 
medicine, namely arsenic (ATO; As2O3) further improved APL treatment. ATO 
targets the PLM moiety of the PML-RARα fusion protein and induce apoptosis of 
APL cells [48, 49]. During the last decade several clinical trials has shown promising 
results for the combination of ATRA/ATO in APL treatment [50].  
1.3.2 The NB4 cell line  
In 1991, an ATRA-maturation inducible cell line (NB4) were isolated from an acute 
promyelocytic leukemia (APL) patient in relapse [51]. After long-term ATRA 
treatment of the initially isolated NB4 cell line, a maturation resistant sub-line NB4-
RAr (NB4-Retinoic Acid resistant) was also isolated [52, 53]. The NB4 cell (and the  
RAr sublines R1 and R2) bear the APL specific t(15;17) chromosomal translocation, 
and are currently the only human APL cell lines available. The NB4 cell lines are 
unique tools to investigate in vitro biological responses of APL, and have been the 
major cell line used in Paper I of this thesis. The NB4-RAr is the only ATRA-
resistant cell line with the t(15;17) chromosomal translocation (APL specific), and the 
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occurrence of this subpopulation in APL patients may explain why patients invariably 
experience relapse with resistance to retinoic acid (RA). However, in vitro maturation 
of these “resistant” cells is possible using cAMP-elevating agents or stable cAMP 
analogs when the cells have become maturation competent using RA beforehand, a 
situation described as RA priming and cAMP triggering [53]. Since cAMP stimulates 
ATRA-induced maturation of ATRA “resistant” APL blasts [53], cAMP agonists 
have been contemplated as adjuncts to APL therapy [54-56]. Together, this creates 
the basis for initiating Paper I. 
1.4 cAMP signaling 
Second messengers are small molecules transmitting extracellular signals (from 
hormones, growth factors and neurotransmitters) to the inside of the cell, where they 
orchestrate a network of signaling events leading to a myriad of cellular actions. 3'-5'-
cyclic adenosine monophosphate (cAMP) was the first second messenger to be 
discovered more than 40 years ago [57], and has since then been the basis of research 
awarded with three Nobel prices (1971, 1992 and 1994). cAMP regulates a range of 
physiological processes, and are involved in almost every known cellular function 
such as  metabolism, gene transcription, cell division, growth and differentiation, 
apoptosis, secretion and neurotransmission [58]. It is produced from ATP upon G-
protein coupled receptor (GPCR) activation of adenylyl cyclase [59], giving an 
overall 1000-fold amplification of the initial signal [60]. The mammalian adenylyl 
cyclases are usually transmembrane receptors and are encoded by nine genes and 
constitute several splice variants [61]. The level of free cAMP in the cell is controlled 
by hydrolyzing phosphodiesterases (PDEs). The PDE superfamily currently 
constitute 11 families and more than 50 enzymes with different properties [62]. With 
so many different proteins involved in cAMP synthesis and degradation it is 
undisputed that regulation of cAMP in the cell is highly prioritized. Today, three 
receptors for cAMP are identified; cAMP dependent protein kinase A (PKA), the two 
isoforms of the exchange proteins directly activated by cAMP (Epac1/2) and cAMP 
ion channels (Fig. 1.4). 
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1.4.1 Protein kinase A  
Most of the intracellular effects of cAMP are mediated via protein kinase A (PKA), 
which is one of the most studied protein kinases. Inactive PKA presents as a tetramer, 
consisting of a regulatory (R) dimer subunit and two catalytic monomer subunits (C). 
Two mammalian R isoforms have been identified [63], with the RI distributed freely 
in the cytoplasm and the RII being mostly membrane-bound via PKA-anchoring 
proteins (AKAPs). The regulatory isoforms are further subdivided into RIα, RIβ, RIIα 
and RIIβ which is encoded by separate genes, and show different tissue distribution. 
Four different C-subunits are described (α,β,γ and PrKX), which is further sub-
divided based on post-translational modifications or splice variants [62]. Upon 
intracellular increase of cAMP, two molecules of cAMP binds to the A and B site of 
each R subunit, inducing a conformational change in the tetramer, leading to 
dissociation of the two C-subunits [64]. These catalytic subunits will subsequently 
phosphorylate a variety of both cytosolic and nuclear proteins (reviewed in [65]) (Fig. 
1.4). An important regulation of PKA is the involvement of PKA-anchoring proteins 
(AKAPs), which allow specificity of PKA signaling by constraining it to different 
compartments of the cell, close to specific effectors and substrates [66], and 






Figure 1.4 Overview of cAMP signaling. Most cAMP effects are mediated by PKA type I and II, as 
well as the newly recognized Epac 1/2. Ligand binding to G-protein coupled receptors (GPCR) leads 
to activation of heterotrimeric G-proteins. The dissociated Gαs activates transmembrane Adenylyl 
Cyclase to synthesize cAMP (red dots) from ATP. Soluble AC is depicted as sAC. Binding of two 
molecules of cAMP to the R subunit of PKA lowers the affinity for the C subunit which will 
dissociate and catalyze phosphorylation of cytosolic proteins or translocate to the nucleus where it 
phosphorylates nuclear targets like cAMP –response element binding protein (CREB). PKA-II 
usually presents in association with A-kinase anchor proteins (AKAP). When stimulated by cAMP, 
Epac  activates Rap1,2 by exchanging the GDP to GTP. cAMP signaling is negatively regulated by 
both phosphodiesterase (PDE) and the protein kinase inhibitor (PKI) in the cytoplasm and nucleus 




1.4.2 Modulation of intracellular cAMP using PGE2, PDE inhibitors 
and cAMP analogs 
Induction of intracellular cAMP production can be manipulated at any level in the 
cAMP production cascade. Receptor agonists such as prostaglandin E2 (PGE2) will 
activate adenylyl cyclace through Gαs, and hence, increase the endogenous level of 
cAMP. Simultaneously, it is preferable to inhibit cAMP breakdown using 
phosphodiesterase (PDE) inhibitors such as isobuthylmethylxantine-IBMX (non-
selective) or rolipram (PDE4 spesific). Since receptor mediated activation of cAMP 
can be attenuated  by Gαs (stimulatory) to Gαi (inhibitory) switch [67] this can be 
overcome by activation of downstream targets such as cAMP receptors inside the cell 
using cAMP analogs. Since the discovery of cAMP in 1961, hundreds of synthetic 
analogs have been produced and tested for their therapeutic potential. Unfortunately, 
undesired side effects, metabolic instability, low cell penetration and the lack of 
tissue specificity were limiting factors for almost all of the first generation analogs. 
The N6-modified cAMP analogs like N6-benzoyl-cAMP (N2-benz-cAMP) and N6-
monobuturyl-cAMP (N6-MB-cAMP) have improved lipophilicity compared to 
cAMP, and are inefficient Epac activators while being full PKA activators [68]. 2´-O-
methyl substitution of cAMP improved the selectivity for Epac 10-100 fold, and 
phenylthio substitution at position 8, particularly with a MeO- or Cl- at para-position, 
improved the selectivity even more. The combination of these two modifications 
resulted in the Epac specific agonist 8-para-chlorophenylthio-2´-O-Methyl-cAMP 
[68], commercially named 007. At present, there exists no single analog to 
discriminate between the type I and type II subtype of PKA, but this can be achieved 
by using specific analog pairs as done in Paper I of this thesis. While the above-
mentioned cAMP analogs are referred to as activating analogs, there also exists 
inhibitory analogs, namely the Rp-cAMPS where the equatorial (Rp) oxygen is 
replaced by sulfur. These analogs are generally antagonistic or partially agonistic 
[69]. The use of synthetic cAMP analogs, targeted to specific proteins, are used as 
standard tools in current signal transduction research to study cell responses as well 
as mapping these responses to specific signaling pathways. An advantage of cAMP 
analogs is that they act within minutes, rather than hours or days, and can be easily 
 26 
removed by washing the cells when applied in a cell culture system. In addition, the 
analog approach does not depend on artificially over expressed gene products, and 
can be used when transfection or microinjection is not applicable, e.g. in leukemia 
cells. 
1.5 Anthracyclines 
The idea of using chemotherapy as treatment for cancer dates back to the first world 
war, when mustard gas used in chemical warfare was discovered to be a potent 
suppressor of hematopoiesis [70]. Since then many new drugs have been developed, 
and today more than 100 cytostatic drugs are used either alone or in combination. 
These drugs vary widely in their chemical composition, physiological properties, 
delivery, specificity and side effects. However, a common feature is their ability to 
affect cell division or DNA synthesis in fast-dividing cells. Anthracyclines are 
cytotoxic antibiotics and are among the most effective antitumor drugs ever 
developed, widely used in the treatment of hematological disorders as well as solid 
tumors. The two first anthracyclines, Daunorubicin (DNR) and Doxorubicin (DOX) 
were isolated in the 1960s from the actinobacteria Streptomyces peucetius [71, 72]. 
The anthracyclines consists of a tetracyclic ring structure connected to a sugar group. 
Although very similar in chemical structure, their physiological properties and 
clinical application may be diverse (Fig. 1.5). 
 
Figure 1.5 The molecular structures of daunorubicin and three similar anthracycline drugs 
(doxorubicin, epirubicin, idarubicin). 
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1.5.1 The anti-tumor mechanism of anthracyclines  
After entering the cell through passive diffusion [73], anthracyclines bind the 
proteasome and the complex translocates into the nucleus of neoplastic and 
proliferating cells [74]. With higher affinity for the DNA molecule, anthracyclines 
intercalates between base pairs and thus  inhibits macromolecular synthesis, which 
was the first explanation for the antitumor effect of anthracyclines  [75]. Also, 
covalent modifications have been observed both in vitro and in vivo where the iron-
complex of the drug participates to produce a covalent attachment to the G-bases of 
the DNA. This creates a interstrand cross linker [76], and may enhance chromatin 
aggregation. A more recently discovered anthracycline target is the chromosomal 
protein Topoisomerase II [77]. Being “Topoisomerase poisoners”, anthracyclines 
stabilize an intermediate complex where the strands are cut and covalently linked to 
the enzyme. This hinders the relaxation of supercoiled DNA and block subsequent 
replication and transcription [78]. The final consequence is growth arrest in G1/G2 
followed by programmed cell death  [79]. Although numerous studies demonstrate 
anthracycline induced production of reactive oxygen species, evidence indicate that 
oxidative stress is unlikely to explain the anti-tumor effect [80, 81], but are of greater 
importance when describing the cardiotoxic side effects mediated by anthracyclines 
[82-87]. 
1.6 Reactive oxygen species (ROS) 
Free radicals are characterized by the presence of one or more unpaired electrons, and 
thus are extremely reactive compared to their electron paired counterparts. There are 
several different radicals, but those derived from oxygen are of most concern in 
biological systems, and are collectively known as reactive oxygen species (ROS). 
ROS are produced as necessary intermediates in a variety of normal biochemical 
reactions were they act as intracellular signaling molecules [88]. Under physiologic 
conditions, the level of ROS is kept low and in balance by biochemical antioxidant 
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systems, when this critical balance is disrupted, oxidative stress occurs as a 
consequence of excess ROS. The mitochondrial respiratory chain is a major source of 
ROS, with 1-2% of the consumed oxygen  being converted to superoxide [89], and 
even increase during hypoxia [90]. A common type of ROS is the superoxide radical, 
which is efficiently converted into hydrogen peroxide (H2O2) by superoxide 
dismutase (SOD). H2O2 may be converted into water by the enzymes catalase or 
glutathione peroxidase, or produce the highly reactive hydroxyl radical (OH˙) via the 
Fe2+-catalyzed Fenton reaction (for review see [91]). Unlike superoxide and hydrogen 
peroxide, hydroxyl radicals cannot be eliminated by enzymes. Therefore, hydroxyl 
radicals are highly toxic compounds, reacting with any substance in its vicinity such 
as lipids, nucleic acids and proteins [92]. Whenever free radicals are generated in 
living cells, the cellular response depends upon the cell type, in addition to 
intracellular localization, amplitude, life span and the type of reactive species [93]. 
1.7 Cardiotoxic side effects of anthracyclines 
As mentioned previously, anthracyclines are among the most effective drugs used in 
oncological practice. Unfortunately, their clinical use is hampered by side effects in 
healthy tissue, most notably in the form of chronic cardiomyopathy and congestive 
heart failure (CHF) [81]. The risk of toxic cardiomyopathy is restricting the 
cumulative dose of these drugs, and therefore may reduce their therapeutic potential. 
Anthracycline induced cardiotoxicity is divided into subcategories depending on the 
time of manifestation. Acute or subacute cardiotoxicity are rare and occur during, 
immediately after or within a week of drug administration. The injuries may be 
transient electrophysiological abnormalities, pericarditis-myocarditis syndrome or 
acute left ventricular failure [94-97]. Early chronic cardiotoxicity is more common 
and usually presents within a year. It usually presents as dilated cardiomyopathy in 
adults and restricted cardiomyopathy in pediatric patients [98-100]. Delayed 
cardiotoxicity was described in the early 1990s among survivors of childhood cancer 
[101, 102]. These cancer survivors may have normal cardiac function for longer 
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periods, but experience ventricular dysfunction [102-104], heart failure and 
arrhythmias [101, 102, 105] years to decades after completion of chemotherapy.  
1.7.1 The cardiotoxic mechanism 
It is of general agreement that the mechanism of anthracycline induced cardiotoxicity 
is different from those mediating their antitumor effect. This is a very important 
concept enabling strategies to prevent cardiotoxicity without diminishing the 
antitumor effect. As with the antitumor effect of anthracyclines, the cardiotoxicity of 
these drugs have been the subject of considerable controversy and numerous 
pathways have been proposed and studied. However, intramyocardial production of 
reactive oxygen species (ROS) is generally accepted as a strong candidate. This was 
indeed documented during the mid-70s with in vitro studies showing ROS production 
from both doxorubicine (DOX) and daunorubicine (DNR) [106, 107]. Concurrently, 
Myers et al. showed amelioration of anthracycline induced cardiotoxicity by Vitamin 
E (alpha- tocopherol) without interfering with its effectiveness as an anti-tumor agent 
[82]. This enforced oxidative stress as the new theory explaining anthracycline 
induced cardiotoxicity, and was subsequently strengthened by the cardioprotective 
effect of the iron-chelator dextrazoxane [83], as well as several studies with 
transgenic animals overexpressing physiological antioxidants [84-87]. The chemical 
structure of anthracyclines is the basis for its ability to induce ROS formation, with 
the quinone moiety notorious for undergoing redox cycling. As seen from figure 1.6,  
the quinone form of anthracyclines is reduced to the unstable semiquinone form by 
P450 reductase, particularly in myocardial cells with high levels of  flavin reductases 
[108]. This semiquinone is rapidly oxidized back to its original form, simultaneously 
creating superoxide anions. The latter can dismutate to form hydrogen peroxide 
(H2O2) and then hydroxyl radical, or it can react with nitric oxide to form 
peroxynitrite (ONOO−). The notorious consequence of this cascade includes 
peroxidation of lipids and oxidative damage to proteins and DNA [109]. One can ask 
the question why the heart as an organ would be so vulnerable to free radicals, and 
the answer may be attributed to its highly oxidative metabolism and low amount of 
antioxidant defense [110]. In addition, since anthracyclines selectively down-regulate 
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glutathione peroxidase [110], cardiomyocytes encounter high levels of hydrogen 
peroxide. Cardiomyocytes are rich in mitochondria, giving rise to 50% of the total 
cell mass which makes the them both a source and a target of ROS [109].  Finally, 
anthracyclines seem to be more retained within cardiomyocytes than other cell types 
[111], maybe due to its high affinity for cardiolipin, a phospholipid mainly present in 
the mitochondrial membranes of the heart [112].
 
 
Figure 1.6 The chemical structure of doxorubicin is the basis for its ability to induce the formation of 
ROS and is similar for daunorubicine, the anthracycline used in this thesis. Doxorubicin (and 
daunorubicine) consists of a tetracyclic ring containing adjacent quinone-hydroquinone groups in 
rings C–B, coupled with the sugar daunosamine attached by a glycosidic linkage to the ring A. One-
electron reduction of the quinone moiety results in the formation of a semiquinone radical that 
creates a superoxide anion when regenerated back to its the parent quinone. This initiates a reaction 
cascade with the formation of other reactive oxygen and nitrogen species (ROS, RNS) (figure from 
[109]). 
 
1.7.2 Strategies to prevent cardiotoxicity 
Since the manifestation of the cardiotoxic side effects is highly correlated to the total 
(cumulative) dose of the anthracycline given, the rationale was first and foremost to 
limit the total administration dose of the anthracyclines. Today there are maximum 
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recommended cumulative doses for all anthracyclines, such as 450 and 900 mg/m2 
for doxorubicin (DOX) and daunorubicin (DNR), respectively [113]. However, there 
is always an associated cardiotoxic risk when using anthracyclines. Some patients 
tolerate cumulative doses twice as large as recommended, while others experience 
cardiac injury at standard doses [114]. Another strategy to prevent anthracycline 
induced cardiotoxicity is altering the administration schedule, since cardiotoxicity is 
related to peak anthracycline doses. Several reports suggests that continuous infusion, 
compared to a single bolus injection of the drug, reduce the risk of cardiotoxicity 
[115, 116], while others found no relationship between administration schedule and 
cardiotoxicity [117]. Anthracycline analogues have been synthesized and tested for 
their ability to replace the conventional DOX and DNR, but none of them has shown 
convincing results in being more cytotoxic and less cardiotoxic [118].  However, 
some of these analogues, such as epirubicin and idarubicin, have shown decreased 
cardiotoxicity in preclinical and clinical studies [119, 120]. The introduction of 
liposomal anthracyclines changed tissue distribution away from sensitive organs such 
as the heart, as they cannot pass areas with tight capillary junctions. In addition, the 
drug release is slower and therefore high peak concentrations can be avoided [121]. 
Another possibility is combining anthracycline treatment with cardioprotectants. 
Several agents with antioxidant properties  such as Probucol [122], Amifostine [123], 
Carvedilol [124] and Sildenafil [125] have shown promising cardioprotective effects 
in vitro and in vivo. However, the iron-chelator Dexrazoxane is the only agent with 
proven cardioprotective effect, defined by reduced signs of congestive heart failure 
(CHF) in cancer patients receiving chemotherapy [126]. Finally, prevention or 
attenuation of anthracycline mediated cardiotoxicity have been demonstrated in 
animal studies by increasing endogenous antioxidants or introducing exogenous 
antioxidants. Although Vitamin E, Vitamin A and carotenoids individually 
demonstrate cardioprotective effects [82, 127-130], Stahl and Sies stated that a 
cocktail of antioxidants in naturally occurring compounds have far more profound 
effects due to synergistic actions of the individual compounds [131]. In Paper II we 
investigated the cardioprotective effect of dietary supplementation with the 
antioxidant-rich red palm oil.  
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1.8 Red Palm Oil 
Red Palm Oil (RPO) comes from the fruit of the oil palm (Elasis guineensis) and has 
been used as a nutritional source as well as medicine for more than 5000 years. 
Throughout history, RPO has been the primary source of dietary fat, and until modern 
medicine, also the choice of remedy for almost every illness in Africa and south-east 
Asia. It is a balanced oil with 50% saturated fatty acids in addition to 40% and 10% 
mono- and polyunsaturated fatty acids, respectively. More importantly, it contains a 
spectrum of vitamins and antioxidants such as carotenoids (vitamin A), tocopherols 
and tocotrienols (Vitamin E) [132]. RPO can be described as “a powerhouse of 
nutrition”, and is of high value in the treatment and prevention of malnutrition and 
vitamin deficiency. Being a good mix of fat and vitamins, RPO provides children 
with the daily recommended amount of Vitamin A from just one teaspoon. Further, 
RPO is regarded as a potent anti-cancer food due to its high content of antioxidants, 
especially tocotrienols. Tocotrienols are one of the most potent anticancer agents of 
all natural compounds [133] and has shown anti-proliferative and pro-apoptotic effect 
for skin, stomach, prostate, breast and other forms of cancer (for a review see [134]). 
During the past two decades, the effect of RPO on the cardiovascular system has been 
intensely investigated. Surprisingly, RPO is cardioprotective despite being the source 
of large amounts of saturated fat. Dietary RPO have shown to reverse the process of 
atherosclerosis [135], improve cholesterol levels [136, 137] and protects against 
ischemia induced stress [138]. In addition, it is an undisputed fact that countries with 
particularly high consumption of red palm oil, such as Malaysia, Indonesia and Papa 
New Guinea, are among the countries with the lowest incidents of heart disease.  
1.9 Myocardial ischemia and reperfusion 
Myocardial ischemia is a state where a coronary occlusion hinders the normal arterial 
blood supply to parts of the myocardium, which impairs normal oxidative metabolism 
[139]. The crucial initiating event leading to an occlusion is endothelial dysfunction. 
Each of the primary risk factors for coronary artery disease (hypercholesterolemia, 
hypertension and free radicals due to smoking) leads to endothelial injury, and hence, 
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entry of lipoprotein molecules and subsequent invasion of macromolecules into the 
intima of the artery wall [140]. The eventual result is formation of an atherosclerotic 
plaque, ready to rupture and initiate the formation of a potentially fatal thrombus. 
Following a cascade of ischemic events the final consequence is irreversible tissue 
damage as a result of apoptosis and necrosis [139]. 
1.9.1 The underlying mechanism of acute myocardial ischemia 
The heart is fully dependent on aerobic metabolism to make energy in the form of 
adenosine triphosphate (ATP) by mitochondrial oxidative phosphorylation. During 
ischemia, the myocardium switches to anaerobic metabolism via glycolysis in order 
to produce ATP. However, glycolytic production of ATP is not sufficient to cover the 
energy demand of the ischemic myocardium and to sustain the hearts contractile 
function [141, 142]. The two main consequences of ischemia are lack of adequate 
amounts of oxygen and nutrients, and reduced washout of metabolites such as lactate, 
protons, NADH2 and CO2 [139] (Fig. 1.7 A). The increase in anaerobic glycolysis 
leads to cellular acidosis, and together with accumulation of other metabolic waste 
products, this will inhibit  glycolysis and further reduce the levels of ATP [143]. The 
reduced energy level will subsequently inhibit ATP-powered ion pumps and lead to 
intracellular ionic alterations [144]. Excess internal sodium increase the osmotic 
pressure and cause cell swelling and rupture [145], while  calcium overload will 
induce electrical and mechanical abnormalities in cardiac tissue [146]. 
Simultaneously, accumulation of free fatty acid metabolites, together with acidosis 
induced lysosomal activation, may cause membrane injury [144]. The presence of 
residual oxygen during ischemia will produce and accumulate reactive oxygen 
species (ROS), which in turn may damage the cell membrane and further depolarize 
the mitochondria [147]. Taken together, the final events inducing myocardial 
infarction is mitochondrial damage due to calcium overload, general membrane 
damage and proteolysis, all leading to myocardial cell death via apoptosis, necrosis 







Figure 1.7 The main events of ischemia (A) and reperfusion (B) leading to myocardial infarct: (A) 
Reduced oxygen supply during ischemia will depress mitochondrial metabolism and results in 
reduced production of ATP while incomplete residual mitochondrial respiration will produces 
reactive oxygen species (ROS). With reduced respiration comes loss off membrane potential leading 
to reversal of the ATP synthase and hence hydrolysis of ATP into ADP and inorganic phosphate. 
Reduced wash out will accumulation lactate, protons and CO2 and lead to cellular acidosis and 
proteolysis. Depletion of ATP inhibit ATP dependent ion pumps resulting in increased cytosolic 
[Ca2+] due to Na+/H+ exchange and reversal of Na+/Ca2+ exchanger. The ischemic cascade culminates 
in cell death either by necrosis or apoptosis. (B) Reperfusion gives a sudden oxygen burst, which 
increases ROS production. Removal of extracellular H+ induce Na+/H+ exchange and further increase 
cytosolic [Ca2+] due to Na+/Ca2+ exchange. Subsequent mitochondrial [Ca2+] overload will together 
with ATP metabolites and increased ROS trigger opening of the mitochondrial permeability 
transition pore (mPTP).  mPTP opening will depolarize mitochondria, and hence,  induce additional 
ROS production  and accelerate mPTP opening,  finally culminating in cell death (figure modified 
from [148] ). 
 
 
1.9.2 Lethal reperfusion induced injury 
Reperfusion is the restoration of blood flow to the ischemic area, and is a prerequisite 
to salvage affected myocardial tissue after an ischemic insult. Clinically, reperfusion 
is achieved by thrombolytic treatment, percutaneous coronary intervention (PCI) or 
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coronary artery bypass surgery. Paradoxically, reperfusion per se may contribute to 
the total infarcted area [141], a term described as lethal reperfusion injury, and is 
defined as injury to the tissue arising when the blood supply returns to the 
myocardium after a period of ischemia [149]. Other myocardial reperfusion-induced 
injuries are; 1) temporal depression of function known as myocardial stunning, 2) 
reduced perfusion due to microvascular damage and 3) reperfusion arrhythmias 
[150]. The existence of lethal reperfusion injury was for a long time highly debated, 
but today its existence is accepted as a contributor to the final infarct size after a 
prolonged period of ischemia followed by reperfusion. Proof of its existence, is the 
presence of viable cells after an ischemic event, which lose viability during the first 
hours of reperfusion [151]. In addition, administration of pharmacological agents at 
the immediate onset of reperfusion reduces the extent of cell death after an ischemic 
episode [18, 152-154]. The main event linking reperfusion injury to cell death is the 
opening of the mitochondrial permeability transition pore (mPTP) (Fig. 1.7 B). This 
is a Ca2+ and ROS dependent process [155], that is inhibited by the acidic 
environment during ischemia [156, 157]. Opening of the mPTP leads to influx of 
solutes and water, followed by swelling of the mitochondrial matrix. Subsequently, 
the outer mitochondrial membrane burst, and various pro-apoptotic substances leak 
into the cytosol and initiates apoptosis [158]. Since the discovery of the mPTP, 
research has focused on inhibition of the pore at reperfusion, a process shown to be 
cardioprotective by reducing the extent of lethal reperfusion injury [158-160]. 
1.10 Modulation of ischemia-reperfusion induced injury 
The achievements in cardiology regarding early reperfusion strategies have greatly 
improved the survival of patients with acute coronary syndromes. However, a 
limitation in the current clinical reperfusion strategies, such as thrombolysis, 
percutaneous coronary intervention (PCI) or coronary artery bypass surgery, is that 
they do not reduce the cellular consequences of lethal reperfusion induced injury. 
During the last decade, our understanding of the mechanisms underlying  reperfusion 
induced injury has been substantially enhanced, and animal studies have revealed that 
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lethal reperfusion injury contributes to nearly half of the total infarct size (Fig. 1.8) 
[161]. Different ways to limit or delay cardiomyocyte cell death have emerged in the 
laboratory and are evaluated as clinical candidates to further improve the outcome in 
patients suffering from acute myocardial ischemia (AMI). Since mPTP opening 
seems to be the “point of no return” in lethal reperfusion injury, a substantial amount 
of  research has focused on manipulating the intracellular milieu away from what 
facilitates mPTP opening during early reperfusion, such as maintaining acidosis 
[162], reducing Ca2+ overload [163] and scavenging ROS [164]. Other 
cardioprotective strategies include pharmacologic interventions and sub lethal 
ischemic conditioning. Many of these cardioprotective interventions have common 
features on their way to inhibit mPTP opening, involving the reperfusion injury 





Figure 1.8 The figure illustrates the necessity of reperfusion to salvage the myocardium and also the 
benefits of a therapeutic intervention to prevent lethal reperfusion injury. Nearly 50% of the total 
infarct size is due to lethal reperfusion injury presenting it as an important target for additional 
cardioprotection (figure from [161]). 
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1.10.1 Reperfusion Injury Salvage Kinase Pathway (RISK) 
The RISK pathway is a “mind-made” and currently expanding signaling cascade, 
describing the molecular events mediating cardioprotection at the time of reperfusion. 
It was named by Hausenloy and Yellon in 2004, and involves activation of particular 
anti-apoptotic protein kinases such as PI3K-Akt and MEK1/2-Erk1/2 [153]. Later, 
many other kinases have been included in the RISK pathway such as protein kinase 
A, C and G (PKA, PKC, PKG) as well as ribosomal protein s6 kinase (p70s6k) and 
eNOS [165] (Fig. 1.9). A variety of agents have the ability to convey cardioprotection 
by activating the RISK signaling pathway (for review see [165]). Different RISK 
agonists mediate a signaling cascade from the cell membrane to the mitochondria, 
converging on the glycogen synthase kinase 3β (GSK3β) [166]. Inhibition of the 
mitochondrial permeability transition pore (mPTP) represents the end-effector which 
may involve activation of the mitochondrial ATP-sensitive potassium channel 
(mitoKATP). A more recently described signaling pathway is the survivor activating 
factor enhancement (SAFE) pathway introduced by Lecour in 2009 [167]. This 
signaling cascade involves the innate immune system and activation of the 













Figure 1.9 A simplified overview of the components linking IPC and IPost to cardioprotection. 
Autacoid activation of G-protein coupled receptors (GPCR) activates the reperfusion injury salvage 
kinase (RISK) pathway either via PI3K/Akt or MEK/ERK signaling cascade. The different signaling 
pathways converge on the mitochondria, with inhibition of the mitochondrial permeability transition 
pore (mPTP). Inhibition of mPTP may be direct, or via activation of the mitochondrial ATP-sensitive 
potassium (mitoKATP) and increased ROS production (figure from [168] ). 
 
1.11 Cardioprotective therapies 
1.11.1 Ischemic conditioning 
Ischemic conditioning (IC) entails cycles of alternate sub lethal ischemia and 
reperfusion, applied to the heart either before (preconditioning) [169] or after 
(postconditioning) [170] a lethal period of myocardial ischemia (index ischemia). 
Since its discovery in 1986 [169], the cardioprotective effect of  Ischemic 
Preconditioning (IPC) has been demonstrated in all species tested, including humans, 
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as well as non-cardiac tissues such as brain, liver, gut, bladder and skin [171]. A 
limitation of IPC as a clinical intervention is the prerequisite to be administered prior 
to the index ischemia, making it relevant only in planned cardiac procedures such as 
coronary artery bypass graft surgery. On the other hand, Ischemic Postconditioning 
(IPost) is applied to the heart at reperfusion to modulate the outcome of acute 
myocardial infarct, and therefore represents a more clinical relevant procedure. 
During both the pre- and post-conditioning phase several autacoids such as 
adenosine, bradykinin, opioids, norephinerine and cytokines are released and initiate 
a variety of signaling pathways within the same or nearby cells [172]. Regarding IPC, 
it is self-evident that signaling during the preconditioning phase is necessary to 
transduce signals from the cell surface to intracellular targets for condition initiated 
cardioprotection [173]. Intriguingly, the signaling pathways recruited at the first few 
minutes of reperfusion are equally important for IPC mediated cardioprotection 
[174]. In fact, the signaling pathways recruited at the onset of reperfusion during both 
IPC and IPost are highly similar, involving  cell surface receptors, protein kinases, 
redox signaling and finally inhibition of mPTP (for review see [168]) (Fig. 1.9). 
1.11.2 Pharmacologic therapy (insulin, GSK3βi and CRF) 
The invasive nature of both IPC and IPost involves series of inflations and deflations 
of a PCI balloon at the occluded area in a infarct-related artery. This may destabilize, 
and hence, loosen parts of the atherosclerotic plaques/thrombus which may cause 
additional occlusion downstream. As an alternative, pharmacologic intervention using 
a variety of different agents, has shown to be cardioprotective in pre-clinical studies 
[165], with activation of similar signaling pathways as observed for IPC and IPost 
[173]. Pharmacologic therapy may therefore be suitable alternatives to the 
mechanical IPC and IPost interventions. In Paper III and IV we explore the 
cardioprotective effect of insulin, corticotropin releasing factor (CRF) and a direct 
GSK3β inhibitor. 
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Insulin reperfusion therapy 
Insulin is a peptide hormone produced in the pancreas and is central in the regulation 
of carbohydrate and fat metabolism in the body. The insulin receptor (INSR) is a 
heterotetrameric glycoprotein situated in the plasma membrane. The two extracellular 
-subunits make up the insulin binding domain, while the two intracellular -subunits 
constitute the receptor tyrosine kinase (RTK) domain. Upon insulin binding the INSR 
form a dimer and the RTK is auto-phosphorylated, causing substrate binding and 
subsequent activation of signaling pathways such as RISK [175]. Administration of 
the “metabolic cocktail” compromising glucose, insulin and potassium (GIK) reduced 
mortality in patients with myocardial infarction undergoing reperfusion [176]. In 
2001, Jonassen et al. demonstrated in the ex vivo rat heart, that insulin was the 
important cardioprotective component of the cocktail [177]. When present from the 
onset of reperfusion, insulin mediate cardioprotection via the PI3K/Akt/p70s6k 
pathway [152]. Later, insulin has shown to inhibit mPTP opening [178] via NO 
signaling or GSK3β inhibition [159]. In the Paper IV we explore the possible 
additive effect of combining insulin treatment with other cardioprotective strategies.    
Inhibition of Glycogen synthase kinase 3 (GSK3β) 
Glycogen synthase kinase 3 (GSK3) is an evolutionary conserved protein kinase with 
homologs in every eukaryotic specie examined. There are two isoforms of the 
enzyme, namely GSK3α and GSK3β, both exerting catalytic activity towards a 
number of intracellular substrates [179]. The two isoforms have 98% identity in their 
central catalytic domain [180], however, the β isoform has reported to have a 
generally higher catalytic activity than the α isoform [179]. GSK3 was first identified 
as a regulator of glycogen metabolism where it phosphorylates and thereby inhibits 
glycogen synthase, the rate-limiting enzyme in glycogen metabolism [181]. Although 
the original name has stuck, the scope of GSK3 regulation extends way beyond 
intermediary metabolism, as the enzyme has emerged to become an important 
component of fundamental processes including cell fate determination, metabolism, 
transcriptional control, and, in mammals, oncogenesis and neurological diseases 
[182]. Unlike other kinases, GSK3 is constitutively active in resting cells, while 
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becoming inactivated in response to cellular stimuli [183]. Since GSK3β negatively 
regulates downstream signaling mechanisms, phosphorylation, and hence, 
inactivation of GSK3β stimulates many cellular functions by removing the negative 
constraint imposed by GSK3β. It is now 20 years since insulin was shown to be 
involved in GSK3 inhibition [184]. Today we know that inhibition of GSK3 requires 
phosphorylation of an N-terminal serine residue, and that protein kinase B (PKB/Akt) 
is responsible for insulin mediated inhibition of GSK3. The inhibitory N-terminal 
serine can also be targeted by other kinases such as p70 ribosomal S6 kinase-1 
(p70S6K1) and most of the downstream kinases of mitogen-activated protein kinase 
(MAPK) (Fig. 1.10). In addition, inhibitory GSK3 phosphorylation has also been 
demonstrated with cAMP elevating agents or cAMP analogs [185] (reviewed in 






Figure 1.10 Many upstream signaling kinases such as mTOR/p70s6K, protein kinase C 
(PKC), phosphatidylinositol 3- kinase (PI3K)/Akt and MAPK/MAPKAP-K1 are reported 
as inhibitors of GSK3β through phosphorylation at Ser-9. In addition, the commercially 
available GSK3β inhibitor (SB415286) used in Paper IV is depicted. 
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Cardioprotective effect of Corticotropin releasing factor (CRF) 
Corticotropin releasing factor (CRF) is a small hormone and neurotransmitter 
produced in the hypothalamus, where it plays a central role in behavioral and 
autonomic responses to stress, by stimulating the release of adrenocorticotropic 
hormone (ACTH) and b-endorphin from the pituitary [187]. The CRF family of 
peptides mediate their response via CRF receptors type -1 (CRFR1) and type- 2 
(CRFR2). Human and rodents express both receptors, however, with more splice 
variants of CRFR2 such as α, β and γ in humans and α and β in rodents [188]. The 
CRFR2 are situated in the peripheral vascular system with distinct cardiovascular 
responses, such as regulating vagal and sympathetic activity [189, 190]. In addition, 
CRF have shown to have direct cardiac effects in mice [191] , rats [192] and guinea 
pigs [193], probable via the highly expressed CRFR2. Previous results show that CRF 
are cardioprotective against a simulated ischemic event in rat neonatal 
cardiomyocytes [194], and the cardioprotective effect of preconditioned media was 
abolished in the presence of a CRF antagonist, indicating that CRF is released into 
the media during mild stress and act on other cells to stimulate protection [194]. In 
Paper III of this thesis we showed that the cardioprotective effect of CRF was 
mediated via CRFR2 both in cardiomyocytes as well as ex vivo rat heart, a 
mechanism that was dependent on PKA and PKC mediated signaling [195]. 
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2. SUMMARY OF RESULTS 
2.1 Paper I  
Cyclic AMP can promote APL progression and protect myeloid leukemia 
cells against anthracycline-induced apoptosis 
 
Recently, cAMP has been advocated to improve acute promyelocytic leukemia (APL) 
therapy since it enhance all-trans retinoic acid (ATRA) induced differentiation of 
APL cells [53]. This study was aimed to evaluate the influence of cAMP on 
anthracycline induced apoptosis of APL cells, since anthracyclines, such as 
daunorubicin (DNR), are a component of classic APL therapy. To our surprise, we 
found that elevated levels of cAMP antagonized DNR induced death of APL patient 
blasts, ATRA sensitive and resistant NB4 cells, most acute myeloid leukemia (AML) 
patient blasts, and some AML cell lines. Using receptor specific cAMP analogs we 
could determine the mechanism to be dependent on cytoplasmic PKA-I while 
independent of perinuclear PKA-II, an observation that was verified using 
NB4RII knockdown cells.  Pro-apoptotic Bad was strongly phosphorylated at PKA 
site Ser118 in cAMP-stimulated NB4 cells, whether exposed to DNR or not, which 
implies that cAMP-stimulation can release Bcl-2/-Xl bound to Bad and thereby 
protect against DNR. Another PKA substrate, the cAMP-responsive element binding 
protein (CREB), associated with therapy resistance in AML, was highly 
phosphorylated at Ser133 by elevated cAMP (for a summarized overview see Fig. 1). 
The protective effect of cAMP was also demonstrated in a hypoxic mimetic 
environment of leukemic bone marrow, and finally in immunodeficient NSG mice 
transplanted with NB4 cells. Animals given clinically relevant cAMP agonists had 
shorter life span and more rapid terminal weight loss than their corresponding 
counterparts. We conclude that cAMP agonists can accelerate the APL progression 
both in the absence and presence of DNR, and therefore suggests caution in using 






Figure 2.1. Overview of the pathway(s) involved in cAMP promoted protection against daunorubicin 
(DNR) induced apoptosis. (1) Increased levels of cAMP were achieved by prostaglandin E2 induced 
activation of adenylyl cyclase together with inhibitors of cAMP phosphodiesterases 
(IBMX/Aminophylline), or by introducing synthetic cAMP analogs. (2) Two molecules of cAMP 
binds to the A and B site of each R subunit, inducing a conformational change in the tetramer, 
leading to the dissociation of the two C-subunits which can phosphorylate a variety of both cytosolic 
and nuclear proteins.  In unstimulated cells, pro-apoptotic Bad may complex with Bcl-2/Bcl-Xl and 
thereby block Bcl2 pro-survival functions. (3a) cAMP stimulation increased S118 phosphorylation of 
Bad which liberates Bcl-2/Bcl-Xl sequestered by Bad, and may compensate for DNR mediated down 
regulation of anti-apoptotic Mcl-1 in these cells. Since cAMP also showed Bad-independent 
protective effect, a search for additional survival-associated potential PKA targets revealed (3b) 
increased phosphorylation of the PKA specific Ser133 of CREB in NB4 cells. The broadly acting 
cyclin-dependent protein kinase (CDK) 7/9 inhibitor roscovitine (RCV) attenuated the protective 
effect of cAMP stimulators against DNR without affecting the phosphorylation of Bad. This 
supportes the existence of protective actions of cAMP involving CDK-dependent events, possibly 
mediated via PKA activation of CREB induced transcription. 
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2.2 Paper II 
Dietary red palm oil protects the heart against the cytotoxic effects of 
anthracycline  
 
Anthracycline induced cardiotoxicity is directly correlated to the cumulative dose and 
may hamper the therapeutic effect of anthracyclines. Therefore, a current working 
hypothesis is that high enough anthracycline doses can be administered in 
combination with cardioprotectors, such as red palm oil (RPO). Male Wistar rats fed 
a standard rat chow (SRC) diet (control) or SRC supplemented with RPO 
(200ul/day), were treated with 2mg/kg-1 daunorubicine (DNR) (or saline as control) 
on alternated days for a 12 period. After completed treatment protocol, ex vivo heart 
function was evaluated using the Working Heart perfusion apparatus. At the end of 
perfusion protocol, hearts were freeze clamped and the tissue analyzed for mRNA or 
protein changes (RT-PCR and WB) of antioxidant systems and stress signaling 
proteins. We found that RPO diet supplementation improved cardiac function after 
treatment with DNR, with increased aortic output (25%) and coronary flow (26%). 
Also, RPO diet supplementation counteracts DNR mediated down regulation of 
superoxide dismutase 1 (SOD1) and nitric oxide synthase 1 (NOS1) mRNA. For 
SOD1 this was also mirrored at protein level. Finally, RPO prevented DNR induced 
activation of the stress related kinases p38 and JNK, and up regulated the pro-survival 
kinase ERK. Based on our results, circumstantial evidence indicate that RPO 
mediated antioxidant therapy may reduce the harmful consequence of anthracycline 




2.3 Paper III  
Activation of corticotropin releasing factor receptor type 2 in the heart by 
corticotropin releasing factor offers cytoprotection against ischemic 
injury via PKA and PKC dependent signaling.  
 
There is currently no clinical therapy for lethal reperfusion induced injury, which 
makes it an important target for residual cardioprotection. This study aimed to verify 
the possible cardioprotective effect of acute administration of Corticotropin releasing 
factor (CRF) in neonatal cardiac cells and ex vivo rat hearts, and further delineate the 
signaling pathway involved. CRF significantly reduced infarct size to 35.3 ± 3.1% 
from 52.1 ± 3.1% in control hearts.  In vitro, CRF was cytoprotective when 
administered prior to a lethal simulated ischemic event, reducing apoptotic and 
necrotic cell death by 18%. CRF was not protective when administered at the point of 
hypoxic reoxygenation or ischemic reperfusion. CRF induced cardioprotection was 
mediated via CRF receptor type 2 (CRFR2) since cardioprotection was abrogated in 
the presence of the CRFR2 inhibitor astressin-2B. The ERK1/2 inhibitor PD98059 
failed to inhibit cardioprotection in the ex vivo heart while inhibitors of both protein 
kinase A and protein kinase C abrogated CRF-mediated protection both ex vivo and 
in vitro. To summarize, acute pre-treatment with CRF peptide protects the heart from 
a lethal ischemic insult, reducing cell death in vitro and infarct size ex vivo. 
Consistent with previous studies using urocortins [196, 197], CRF mediates its 
protective effect against ischemic stress through CRFR2 activation. Finally, we 






2.4 Paper IV 
Abrogated Cardioprotection and Blunted Akt Phosphorylation when 
Combining Ischemic Postconditioning with Pharmacological 
Reperfusion Therapy 
 
Several pre-clinical studies suggest strategies to reduce reperfusion induced cell 
death, and this study aimed to investigate whether the combination of 
cardioprotective treatments could afford additional effect when compared to the 
treatments given alone. We used the ex vivo Langendorff perfused rat heart model to 
modulate cell injury and evaluate infarct size induced by ischemia-reperfusion. 
Insulin and a direct GSK3β-inhibitor (GSK3βi) administered at immediate 
reperfusion reduced infarct size by approximately 50%. Combination of the two 
treatments did not have additive cardioprotective effect compared to the treatments 
given alone. Further, the cardioprotective effect of insulin and/or GSK3βi was lost in 
the presence of the ROS-scavenger MPG, indicating a ROS dependent signaling 
pathway for cardioprotection. Our data also suggests that cardioprotection induced by 
insulin administration at reperfusion, is mediated via mitoKATP and PKC dependent 
signaling. Surprisingly, the combination of ischemic postconditioning (IPost) with 
either of the two pharmacologic reperfusion therapies (Insulin or GSK3βi), abrogated 
cardioprotection imposed by the therapies given alone. Loss of cardioprotection was 









3.  AIMS OF THE STUDY 
 
The overall aim of this thesis was to participate in the search for ways to directly or 
indirectly minimize anthracycline mediated cardiotoxicity and also to reduce the 
degree of ischemia-reperfusion induced injury.  
 
Paper I:        Evaluate the influence of cAMP on anthracycline induced apoptosis of 
acute promyelocytic leukemia (APL) cells, since cAMP has been 
advocated as adjuvant to classical APL therapy. 
 
Paper II:      Study the possible cardioprotective effect of Red Palm Oil against 
anthracycline mediated cardiotoxicity. 
 
Paper III:    Delineate the cardioprotective effect of corticotropin releasing factor 
(CRF) against ischemia-reperfusion induced injury. 
 
Paper IV:     Investigate the combination of known protective therapies against 





4. METHODOLOGICAL CONSIDERATIONS 
This chapter will describe the main methods used in the thesis, with special emphasis 
on the favorable or unfavorable aspects for the given methods. For a detailed 
description of materials and methods the reader is referred to the articles.  
4.1 Cell culture experiments 
4.1.1 Immortalized cell lines, primary cells and patient material  
Immortalized cell lines is an invaluable resource as they are easy to handle, are a 
limitless self-replicating source and have relatively high degree of homogeneity. 
Several characterized acute myeloid leukemia (AML) cell lines are regarded as 
typical for different AML subtypes, and are often used as in vitro models for AML 
disease. The NB4 cell line used in Paper I was originally isolated from bone marrow 
of an acute promyelocytic leukemia (APL) patient in relapse [51], and is currently the 
only APL specific cell line available. The NB4 cells harbor the t(15;17) translocation 
and differentiates into granulocytes upon ATRA-treatment [51], and undergoes 
apoptosis in response to arsenic trioxide  (ATO) and anthracyclines [198, 199]. The 
NB4-LR1 and NB4-LR2 sublines used in Paper I, represents the two retinoic acid 
“resistant” cell lines, where LR1 but not LR2 has the ability to mature in the presence 
of cAMP. The letter “L” stands for Prof.Lanotte and represents the laboratory from 
which the NB4 subline has been isolated. The HL60 cell line was also isolated from a 
patient with APL, but is a less differentiated variant compared to NB4. It presents 
without the APL specific t(15;17) translocation, and is now recognized to be an AML 
cell line [200], but still has the APL phenotype in response to ATRA [201] . Mv4-11 
is an AML cell line that in contrast to NB4 and HL60 expresses wt p53, which have 
shown to be important for cAMP mediated cell survival [202]. Even though cell lines 
are important tools for biochemical research, one should never neglect the artificial 
aspect of cell lines represented by a homogenous group of immortalized cells. Since 
they can grow continuously in culture, they are prone to genotypic and phenotypic 
changes. Subcultures can arise with the most rapidly growing clones within the 
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culture being selected [203]. Primary cells can be more attractive since they are 
genetically stable and have characteristics very close to the tissue of origin [203]. In 
Paper III we isolated neonatal mouse cardiomyocytes, and within 2 days a confluent 
monolayer of spontaneously beating cardiomyocytes was formed and ready for 
experiment. Also, human primary cells/patient material can be used to determine 
accuracy of extrapolating human data from an animal model, as done in Paper I. 
Although there are advantages of using primary cell lines, their limitations are slow 
doubling time and restricted passages. The strength of a paper will increase when 
including more than one model. In Paper I we have studied several AML cell lines, 
included patient material from 10 AML/APL patients and also an in vivo mouse 
model. In Paper III we have performed experiments on primary mouse 
cardiomyocytes as well as whole heart preparation (Langendorff) from rat. 
4.1.2 Isolation of neonatal mouse cardiomyocytes and simulated 
ischemia 
To evaluate any anti-apoptotic action of corticotropin releasing factor (CRF) against 
ischemia-reperfusion induced injury, neonatal mouse cardiomyocytes was isolated 
and subjected to simulated ischemia. Isolated cardiomyocytes from heart tissue are, 
as expected, fully differentiated and morphologically similar to the cells of the donor 
organ, but presents without interstitial tissue and the presence of other cell types 
which may complicate the measurements in intact tissue. In addition, it enables the 
study of single cell populations subjected to identical defined conditions such as 
media constituents, humidity and partial pressure. The disadvantage of using primary 
cells is the risk of contamination and also the loss of their natural environment with 
regards to neurological input, nutrients and physical contact (cell-cell and cell-
matrix).  The cells may therefore change during isolation which may affect their 
reliability as a physiological cell model. With regards to simulated ischemia-
reoxygenation, control of incubation conditions is easy. However, compared to the 
intact organ, cell-culture presents without the interaction between cardiomyocytes, 
endothelium and the intracellular space.  
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4.1.3 Drug doses and evaluation of apoptosis 
For a cell-culture experiment to be clinically relevant, it is important utilize drug 
concentrations that are comparable to what patients experience during therapy. 
Minotti et al. reported that anthracyclines given in clinical relevant doses induce 
DNA breaks via inhibition of Topoisomerase II, while ROS induced breakage was 
only relevant as supra-clinical doses [81]. In addition, the anthracycline dose also 
influence apoptotic cell morphology, since the classical features of apoptosis such as 
membrane blebbing and chromatin condensation are absent at high doses, a 
phenomenon described as “frozen” cell death [204]. The peak plasma concentrations 
of daunorubicine (DNR) in patients is approximately 5 μM, but most often in the 
range of 1-2 μM [80]. In Paper I, we used both a high (5μM) and also lower doses 
(0.1μM and 0.5μM) of DNR, which are comparable to the measured levels in patient 
plasma. However, different cell lines show varying ability to accumulate drugs 
intracellularly [205], and therefore the intracellular drug concentrations can be 
difficult to predict. Idarubicin (IDA) is a more lipophilic drug compared to DNR, and 
accumulates more easily inside cells. It is considered 4-8 times more efficient in 
inducing apoptosis compared to doxorubicine (DOX) [206]. The IDA doses used in 
Paper I ranged between 0.01-0.5 μM. In vitro determination of cell viability (Paper 
I) was assessed by light microscopy to visualize membrane budding/blebbing, and 
differential interference contrast microscopy to visualize chromatin condensation in 
response to Hoechst staining. This is a well-established routine assay to evaluate 
apoptosis. Evaluation of apoptotic cell death in Paper III was assessed using a 
commercial single-stranded DNA (ssDNA) apoptosis ELISA (Enzyme-Linked 
ImmunoSorbent Assay detection) kit (Chemicon) according to the manufacturer's 
instructions 
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4.2 Animal work 
4.2.1 Animal strain and anastetichs 
In Paper I we established an in vivo leukemic model by transplanting male NOD-
scid IL2rγnull (NSG) mice with NB4 cells (acute promyelocytic leukemia (APL) 
cells). The NSG mouse is the best model to choose for cancer zenograft since it is 
the most immunodeficient mouse (lacking mature T cells and B cells, functional 
natural killer cells and are deficient in cytokine signaling) and therefore easily 
engraft human cells and tissues. In Paper II, III and IV hearts from male Wistar 
rats were used in the ex vivo isolated heart perfusions. Wistar rats are a frequently 
used and all-purpose animal model for biomedical research. In most published 
studies, including our own, we utilize young and healthy animals which may not be 
the best representation of the cancer patient (Paper II) or elderly CVD patient 
(Paper III and IV), which often presents with a complicated medical history and 
treatment regime. As an anesthetic agent we used sodium pentobarbital (i.p 
injection) commonly used for animal research, due to practicality, low cost and 
little to no influence on the study design. Although being a cardio depressant [207], 
it does not influence the final infarct size [208] as is documented for other volatile 
anesthetics such as isoflurane [209]. 
4.2.2 The isolated Langendorff and Working heart perfusion model 
The isolated Langendorff and Working Heart perfused preparations are ex vivo setups 
where the heart is excised from the animal and mounted by aorta to the perfusion 
apparatus. These highly reproducible preparations allow studies of cardio-specific 
effects without the confounding influence of the circulation or neurological factors. 
However, this also makes the model less clinical relevant than an in vivo preparation. 
While oxidation of fatty acids is the main energy source for the in vivo heart, glucose 




The Langendorff heart preparation 
In the Langendorff perfusion setup, first described by Oscar Langendorff in 1895 
[210], the heart is retrogradely perfused with oxygenated Krebs-Henseleit buffer 
(KHB) (37ºC) at a constant hydrostatic pressure (80mmHg) (or constant flow rate). In 
both settings the aortic valve is forced shut, directing the fluid into the coronary ostia, 
perfusing the entire ventricular mass of the heart and finally draining into the right 
atrium. This effluent can be collected and measured (coronary flow; CF). Due to lack 
of serum proteins and blood cells, the KHB have reduced oncotic pressure and 
oxygen-carrying capacity, which increase CF and the risk of edema in isolated hearts 
compared to the in vivo setting [211]. Due to the ex vivo nature of the setup, the heart 
function will deteriorate throughout the protocol at a rate of 5-10%/h depending on 
different factors such as the skills of the operator, specie, perfusion fluid and animal 
age [212]. A water-filled latex balloon connected to a pressure transducer is inserted 
into the left ventricle, via the left atrium, enabling functional data such as heart rate 
(HR), left ventricular developed pressure (LVDP) and contractility (dP/dT) to be 
recorded. Great care must be taken when inserting and securing the balloon to 
minimalize the amount of mechanical stress imposed on the heart. Finally, 
maintaining the heart at physiologic temperature is highly necessary as both hypo- 
and hyper-thermia can influence contractility, heart rate as well as the final infarct 
size [213]. Prior to the experiments, a set of inclusion parameters were defined and 
experiments were aborted if they failed to meet these criteria. Our inclusion criteria 
were as followed; at the end of stabilization - LVDP > 80 mmHg and CF; 8-16 
ml/min and at the end of reperfusion - LVDP > 30 mmHg or CF > 4 ml / min. 
The Working heart preparation 
Although the Langendorff perfused isolated heart is beating, it is considered as 
“nonworking” since no perfusate is ejected from the left ventricle. Some major 
modifications were made to the model, and the isolated working heart preparation 
was presented by Neely and Morgan in the 1960s [214]. It is a more complex 
preparation in which the perfusate is delivered to the left ventricle via the cannulated 
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left atrium and ejected in the normal direction via the left ventricle and out the 
cannulated aorta. This preparation is a left ventricular ejecting heart, thereby a heart 
performing work, giving the ability to measure pump function with different filling 
pressures and afterloads. The preload of the preparation is determined by the height 
of the atrial perfusion reservoir relative to the heart, but is usually set to 20 cm for rat 
heart preparations. The left ventricle then pumps the perfusate through the aorta 
against a hydrostatic pressure (afterload), which is determined by the height of the 
fluid column above the aortic cannula and is usually set to 60-100cm for a rat heart. 
In the ventricular ejection phase a portion of the perfusate enters the coronary ostia, 
and thereby perfuses the heart muscle. This coronary flow can be collected and 
measured as described for the Langendorff preparation.  
These two perfusion models (reterograde and working) are optimized for 
investigation of distinct end-points. While the Langendorff setup is a perfect model 
for determination of infarct size, the working heart perfusion is more suitable for 
evaluation of cardiac function [215].    
4.3 Examination of signaling pathways 
4.3.1 Western Blotting 
When doing Western Blot (WB) analysis, proteins are separated by size on a 
polyacrylamide gel and transferred onto a membrane. The primary antibody binds to 
the protein of interest or a posttranslational modification such as phosphorylation. 
The secondary antibody binds the primary antibody, and is conjugated to a reporter 
group which produces a detectible signal when the appropriate substrate is added. 
WB is regarded as a semi-quantitative analysis due to its indirect measurements as 
well as being a multi-step procedure, the latter increasing the possibility of variation. 
As a result, relative quantities of samples on the same blot can be compared. WB 
results are illustrated by presenting representative blots as done in Paper I that can be 
supplemented with the densitometrical readings of all blots as done in Paper II, III 
and IV. Phosphorylated proteins were normalized to the total level of the 
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corresponding protein to determine phosphorylation mediated regulation. To ensure 
equal loading on the gels, housekeeping proteins such as Actin or GAPDH were 
visualized simultaneously as the proteins of interest. 
In Paper II, III and IV, phosphorylated proteins and stress induced proteins were 
analyzed in heart tissue. To minimalize the amount of handling induced stress and de-
phosphorylation, hearts were allowed to stabilize for 20 min before introducing 
regional ischemia (Paper III and IV), snap frozen in liquid nitrogen at the end of 
perfusion protocol and lysed in in the presence of protease inhibitors. 
 
4.3.2 Intracellular Phospho-flow Cytometry 
Flow cytometry is a technique to count and analyze cells in a fluid stream as they 
pass by an electronic detection apparatus. Phospho-flow cytometry combines the 
ability of monoclonal antibodies (mAb) to recognize post-translational modifications, 
such as phosphorylation, and the single-cell analysis of flow cytometry. It is therefore 
a fantastic tool for analyzing signaling pathways, because it can identify cellular 
subpopulations and simultaneously analyze biochemical processes within single cells. 
Constantly, major advances are made to the method, expanding the number of 
simultaneous multiparametric analysis of physical and/or chemical characteristics. 
Compared to more conventional techniques, phospho-flow cytometry can analyze 
multiple parameters in single cells in a heterogeneous and small cell population at a 
rapid pace.  
In Paper I we used phopho-spesific antibodies to investigate the signaling cascade in 
NB4 cells subjected to daunorubicin (DNR) and cAMP. After stimulation, the cells 
were fixed in paraformaldehyde (PFA) and permealized in methanol as suggested by 
Krutzik and Nolan 2003 [216]. Methanol dehydrates the cells and denatures the 
proteins which may destroy epitopes recognized by the monoclonal antibodies 
(mAbs). However, this process is reduced when the methanol is applied ice cold. In 
addition, methanol makes nuclear proteins available which is necessary when looking 
at e.g. the different Stat proteins. Otherwise, it is important to be consistent with 
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regards to time and temperature during fixation, permeabilization and mAb staining, 
since variations may affect measurements of phosphorylation induction [216]. Also, it 
is important to know that the amount of mAb is dependent of volume and not cell 
number, as absolute intensities change almost linearly with mAb concentration [216]. 
4.3.3 qRT-PCR 
Quantitative real time polymerase chain reaction (qRT-PCR) is a method based on 
standard polymerase chain reaction (PCR), and is used to amplify and simultaneously 
quantify a targeted DNA sequence. The results can be presented as an absolute 
number of copies or a relative value when normalized to a reference gene. qRT-PCR 
can produce accurate quantitative data, is sensitive, requires low amounts of RNA 
template, but unfortunately requires expensive equipment and reagents. 
Normalization of gene expression data is used to correct sample-to-sample variation. 
Real-time results are usually normalized to a “housekeeping gene”, coding a protein 
required for basic cellular function with a relatively constant expression in all cells of 
an organism. The qRT-PCR experiments in this thesis (Paper II) are in concordance 
with other cardiac qRT-PCR studies [217], and use glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as the reference gene. In a study on cardiac stem cells, 
GAPDH was the most consistent housekeeping gene under normoxic conditions, 
while beta-actin was the most consistent during hypoxia [218]. However, a recent 
study on the stability of different “housekeeping genes” showed that the anti-cancer 
drug irinotecan upregulate the level of GAPDH in the rat colon. They encourage the 
use of normalization couples, but presented ubiquitin C as the most favorable gene if 
restricted to only one normalization gene (in a rat model of irinotecan-induced 
mucositis) [219]. We should therefore in future experiments consider to normalize the 






5.1 Evaluation of cAMP as adjuvant in APL treatment 
A major concern with conventional cancer therapy is that only subgroups of patients 
respond favorably to a given treatment, and that side effects often limit the dose 
efficiency of the treatment. These two issues are addressed in Paper I and Paper II, 
respectively. Over the years, new treatment modalities with more targeted therapy are 
evaluated, and one successful approach is the use of all-trans retinoic acid (ATRA) in 
acute promyelocytic leukemia (APL), and has changed the prognosis from the most 
rapidly fatal leukemia two decades ago to the most curable leukemia subtype today. 
Current first-line APL therapy is based on differentiation-associated maturation, and 
hence, elimination of the leukemic cells by ATRA, which is combined with an 
anthracycline (Daunorubicine-DNR) to eliminate residual cells [220]. However, the 
occurrence of ATRA resistant cell populations in APL patients may explain why in 
vivo treatments invariably lead to relapse with resistance to ATRA [52]. The ATRA-
maturation inducible cell line NB4 [51] and the maturation resistant sublines NB4-
RAr (R1 and R2) [52, 53] were isolated from an APL patient in relapse. Although the 
NB4-RAr cell lines are retinoic acid (RA) maturation resistant, the R1 subline 
responds to RA by other means (proliferation at low doses) [53], meaning that the RA 
signaling is not defective. Interestingly, the maturation resistant cell line (R1) can 
actually undergo terminal maturation when ATRA is combined with cAMP elevating 
agents [53]. The authors describe this as an RA-dependent priming step making the 
cells competent to undergo maturation, followed by cAMP-dependent triggering of 
the primed cells to undergo terminal maturation [53]. It is clear that both these 
processes are necessary for maturation since the RA resistant R2 subline lack the RA-
dependent component, making it unresponsive to cAMP triggered maturation [53]. In 
addition, subtle changes in cAMP levels using antagonizing cAMP analogs ((RP)-
8Cl-cAMPS) disturbed maturation of RA-sensitive NB4 cells [53]. This emphasizes 
the crosstalk between RA and cAMP as a key component in ATRA mediated therapy, 
where endogenous cAMP seems sufficient for sensitive NB4 cells to mature. An 
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important paper by Ruchaud et al. implies that uncoupled priming and triggering may 
explain APL relapse with resistance to ATRA and advocates cAMP as an adjunct to 
current APL therapy to improve further the long-term survival of these patients [53]. 
Thus, recent studies demonstrate cAMP enhanced ATRA effect on survival of 
syngenic PML-RARA APL mice and mice transplanted with NB4 cells [54-56], and 
also retarded the APL progression in a patient [55]. However, none of these studies 
incorporate anthracyclines in their experiments, and therefore no study has evaluated 
the impact of cAMP on the anti-leukemic effect of anthracyclines which is currently 
an important component of first-line APL therapy. In Paper I we found that cAMP 
abrogate the anti-leukemic effect of daunorubicin (DNR) in acute promyelocytic 
leukemia (APL) cells. These findings suggest awareness when cAMP stimulation is 
considered combined with ATRA to boost APL cell differentiation since the expected 
beneficial effect of cAMP on APL cell maturation may be outweighed by enhanced 
survival of ATRA-resistant APL blasts. Awareness should also be undertaken when 
patients who experience increased cAMP levels are treated with anthracyclines, such 
as patients with inflammatory pulmonary diseases who are treated with 
phosphodiesterase inhibitors.    
5.1.1 The plethora of cAMP signaling 
cAMP is a remarkable regulator of fundamental cell processes, including cell 
proliferation, differentiation and apoptosis [221]. cAMP activity is mainly mediated 
via cAMP-dependent protein kinase A type I and II (PKA I and PKA II) or cAMP-
stimulated exchange factor Epac 1 and Epac 2 [221]. The versatility of cAMP 
signaling is highly represented in hematopoietic cells, with induction of apoptosis in 
thymocytes [222, 223] and the myeloid leukemia (AML) cell line IPC-81[224], while 
protecting mature neutrophilic granulocytes against TNFα induced death [225]. In 
addition, cAMP synergizes with glucocorticoids and PKC signaling in inducing 
apoptosis in immature murine T cells [226, 227], while it cooperates with retinoic 
acid in the differentiation of various leukemia cells, such as NB4 [53, 228, 229]. The 
findings in Paper I present another example of the diverse nature of cAMP signaling. 
We found that cAMP abrogate the anti-leukemic effect of daunorubicin (DNR) in 
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acute promyelocytic leukemia (APL) cells. Protection was dependent on the generally 
cytoplasmic PKA-I rather than perinuclear PKA-II, and was independent of Epac. 
PKA I dependency is also described for cAMP induced apoptosis in the AML cell 
line IPC-81 [230], while recent findings by Nguyen et al. demonstrate that activation 
of both PKA type I and PKA type II is required for ATRA-induced maturation of the 
APL cell line NB4 [231]. cAMP is also involved in heart physiology and pathology. 
In cardiomyocytes, cAMP is the main second messenger, orchestrating the signals in 
sympathetic and parasympathetic systems, mediated via Gs-and Gi-protein 
respectively. More recently, cAMP was found to be involved in the regulation of 
cardiomyocyte cell death. Increased endogenous cAMP protects neonatal rat 
cardiomyocytes against NO-induced apoptosis, a mechanism involving both 
PKA/CREB and Epac/Akt-dependent pathways [232]. Also, cAMP reduces the 
mortality after acute myocardial infarct (AMI) in transgenic mice overexpressing 
adenylate cyclase VI, by attenuating adverse left ventricular (LV) remodeling and 
preserving LV contractile function [233]. It has been documented a nearly twofold 
rise in cAMP levels during myocardial ischemia [234]. Paradoxically, Lochner et al. 
showed cyclic increase in tissue cAMP during the classical multi-cycle 
preconditioning protocol [235], and others have shown that  brief  periods of 
increased tissue cAMP, as a result of β-adrenergic [236] or ischemic preconditioning 
[234, 237], are cardioprotective against a subsequent ischemic period [237-240]. This 
cardioprotection is abolished in the presence of the β-adrenergic blocker alprenolol, 
indicating that temporally dependent increase in tissue cAMP during ischemic 
preconditioning is essential for its cardioprotection [237, 240]. The cAMP receptor, 
PKA, is suggested to be important in the cardioprotective mechanisms of ischemic 
preconditioning [239, 241]. This is supported by Sanada et al. showing that 
pharmacological preconditioning using a PKA directed cAMP analogue protects the 
in vivo myocardium against ischemia-reperfusion injury [239], which cannot be 
achieved using the Epac directed cAMP analog [242]. In Paper III of this thesis, we 
showed that acute pre-ischemic treatment with corticotropin releasing factor (CRF) 
reduced neonatal cardiomyocyte death in vitro and infarct size in intact ex vivo rat 
hearts exposed to lethal ischemic induced stress. The CRF mediated cyto-
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/cardioprotection was mediated through CRFR2 and involved activation of PKC and 
PKA dependent signaling pathways. This involvement of PKA is in contrast to the 
mechanism of urocortin (UCN) peptides against ischemia-reperfusion injury [196, 
197]. Recently, it has been shown that UCN evoke inotropic and lusitropic effects in 
the ex vivo rat heart through Epac activation [243], indicating a link between CRFR2 
and Epac in the heart. 
5.2 The clinical picture of anthracycline mediated 
cardiotoxicity 
Acute and subacute anthracycline induced cardiotoxicity is relatively rare and occur 
in 1-2% of patients [244], while the types of chronic cardiotoxicity is clinically 
significant and requires long-term therapy [114, 245-249]. A highly quoted study by 
Von Hoff and colleagues from 1979, gave early recommendations for a maximum 
dose of 550mg/m2 doxorubicin (DOX) [250], based on relatively low incidence of 
heart failure up to that level. Since then, it has become evident that the predicted 
incidents of anthracycline induced cardiotoxic events was underestimated, as 
suggested by the authors themselves [250]. A large retrospective analysis of three 
Phase III trials, published by Swain in 2003, found the level of cardiotoxic incidents 
to be higher than previously described [251]. They observed an estimated cumulative 
percentage of patients with DOX-related congestive heart failure (CHF) to be 5%, 
26% and 48% at cumulative doses of 400 mg/m2, 550 mg/m2, 700 mg/m2 respectively 
[251]. In addition, they estimated a significant risk of cardiotoxicity at relatively low 
anthracycline doses (200-250mg/m2) [251], an observation supported by others [252]. 
The introduction of the anthracyclines has played an important role in the 
improvement of cancer therapy and has created a population of childhood cancer 
survivors almost reaching 350000 in the US alone (in 2005) [253]. For many 
oncologists the risk of cardiotoxicity has, and for some still are, a pale problem 
compared to the cancer itself. Although presenting as a secondary priority, 
cardiotoxicity must never be ignored. Therefore, research devoted to prevention and 
early diagnosis of anthracycline induced cardiotoxicity is very important. Today, 
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ultrasound or MUltiple Gated Acquisition scan (MUGA) are used to evaluate left 
ventricle ejection fraction before, during and after chemotherapeutic treatment, to 
follow heart function and to early diagnose cardiomyopathy [254]. Unfortunately, 
limited studies with long-term follow up of heart function have been conducted, 
which is necessary since anthracyclines also are used to treat curable tumors which 
enable the patients to live for decades thereafter.  A study of 201 survivors of 
childhood cancer, found 38% and 63% to have abnormal cardiac function, using 
noninvasive imaging, when exposed to 495mg/m2 and 500mg/m2 DOX, respectively 
[102]. In another study, 229 adults treated with DOX during childhood cancer was 
diagnosed with symptomatic (10%) and asymptomatic (6%) heart failure more than 
15 years after treatment [255]. To sum up; anthracycline has contributed to an 
excellent survival rate of childhood cancer patients. Unfortunately, for some the price 
is paid later with cardiac failure, and is an increasing cause of heart transplantation in 
young adults [256].  
5.3 Cardiac antioxidant therapy 
The molecular mechanisms of the anthracycline mediated anti-cancer effect and 
toxicity in healthy tissue are mediated at two fundamental levels, by interference with 
DNA and increased oxidative stress. However, it is fairly accepted that the 
cardiotoxic effect of anthracyclines are attributed to the latter, with elevated levels of 
ROS and interference with mitochondrial function. In addition, a review by Gewirtz 
et al. suggests that the anti-cancer effect of anthracycline at clinical doses is mediated 
by DNA interference and not increased ROS [80]. Still, many oncologists believe that 
ROS induction is an important component of anthracycline mediated removal of 
cancer cells, and therefore do not recommend antioxidant diet/supplementation 
during chemotherapy since it can interfere with the anti-cancer effect of the 
anthracycline. In a systematic review of randomized, controlled clinical trials, none of 
the studies reported any evidence of significant decrease in efficiency of 
chemotherapy when combined with antioxidant supplementation [257]. In fact, most 
studies reported decreased general toxicity in healthy tissue when chemotherapy was 
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accompanied with antioxidant supplementation [257, 258]. Numerous antioxidants 
and ROS scavengers have been in vitro and in vivo assayed for the prevention of 
cardiotoxicity (for review see [259, 260]). As previously mentioned, Stahl and Sies 
[131] stated that a cocktail of antioxidants in naturally occurring compounds have far 
more profound effects due to synergistic actions of the individual compounds. Paper 
II of this thesis report that Red Palm Oil stabilize important antioxidant systems in 
cardiac tissue otherwise down regulated by daunorubicin (anthracycline) [131]. While 
the majority of preclinical studies indicate a potential benefit of certain dietary 
agents, some studies cannot find any benefit of the same antioxidants. For that reason 
the authors “stress the difficulty to extract unequivocal conclusions from such a wide 
number of studies using many different concentrations of antioxidants, in different 
experimental models, and especially with many different doses of the drug” [260]. The lack 
of high quality clinical studies does not enable firm conclusions to be made. Studies 
with long-term follow-up, which can identify late-onset cardiotoxicity, evaluating 
both cardiotoxicity and anti-tumor effect are necessary. Today, only one compound, 
the iron-chelator Dexrazoxane, show consistent cardioprotective effect in preclinical 
[261] and clinical studies [262], without any influence on the anti-tumor effect of the 
drug. The American Society of Clinical Oncology recommends dexrazoxane as a 
cardioprotector for patients with metastatic breast cancer who will benefit from a 
cumulative dose of doxorubicin (DOX) exceeding 300mg/m2. The same is 
recommended for other adult patients, with caution of possible, currently unknown, 
anti-anthracycline effects in mind [263]. As mentioned above, we have shown (Paper 
II) that daunorubicin significantly down regulate cardiac levels of important 
antioxidant systems. Consumption of endogenous cardiac antioxidants, such as 
oxidation of glutathione, are also demonstrated during ischemia-reperfusion e.g. in 
patients undergoing coronary bypass surgery with aortic cross-clamping [264]. 
Several studies, with varying results, have evaluated the cardioprotective effect of 
different antioxidants against ischemia-reperfusion induced injury in patients 
undergoing planned cardiac surgery [264]. The use of N-acetylcysteine (NAC) to 
enhance intracellular glutathione has shown promising results in small-scale trials to 
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improve patient outcome after acute myocardial infarction or surgery induced 
ischemia [265].   
5.4 Modulation of myocardial ischemia-reperfusion injury 
In 1972 it was established that myocardial reperfusion of the occluded coronary 
artery would reduce myocardial infarct size [266]. Today, reperfusion strategies using 
thrombolytic treatment and percutaneous coronary intervention (PCI) represents the 
cornerstones of current therapy for patients suffering from acute myocardial 
infarction (AMI). However, in-hospital mortality of this patient group are still 6-14% 
[267], urging the need for novel interventions to further reduce infarct size and 
improve survival rates of these patients. Although reperfusion is a necessity for 
myocardial salvage, the price to pay is accompanying reperfusion injury (Fig. 1.8). 
There is currently no clinical therapy for lethal reperfusion injury, which makes it an 
important target for residual cardioprotection. Lethal reperfusion injury represents a 
hot area of ongoing research and has led to the discovery of several pre-clinical 
therapies (mechanical and pharmaceutical), with potential of being administered 
simultaneously as classical reperfusion strategies to further reduce the final infarct 
size.  
5.4.1 “From Bench to Bedside” 
Unfortunately, it is often difficult to transfer promising pre-clinical strategies into 
clinical interventions which actually improve the outcome of AMI patients. The 
reason for this may be attributed to confounding factors involving patient selection, 
reperfusion strategy (thrombolytic treatment, PCI or coronary artery bypass surgery), 
administration time of the novel reperfusion intervention as well as varying 
determinants of infarct size such as ischemic time, area at risk, collateral flow and the 
endpoints evaluated for cardioprotection (reviewed in [268]). While coronary heart 
disease (CHD), is caused by or associated with, risk-factors and co-morbidities such 
as aging, hypertension, diabetes and left ventricular hypertrophy [269], most pre-
clinical studies, including our own, evaluate the effect of novel cardioprotective 
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strategies using healthy and juvenile animals. In fact, atrial tissue from elderly [270] 
and diabetic patients [271] was resistant to ischemic preconditioning (IPC) in the in 
vitro hypoxia-reoxygenation model. Further, diabetic patients has twice as high 
glycogen synthase kinase 3β (GSK3β) activity compared to non-diabetic patients, and 
since we (Paper IV) and others [159] have demonstrated an important role for 
GSK3β inhibition during cardioprotection, it is possible that this can explain why the 
protective effect of IPC and IPost are lost in diabetic animal models [272, 273]. 
Another major confounding factor is concomitant patient medication either directed 
against the ongoing MI or associated risk factors and co-morbidities. Several 
independent studies have demonstrated that different pharmaceuticals may actually 
be cardioprotective themselves (β-blockers and ACE inhibitors)  or they can abrogate 
the otherwise cardioprotective effect (anti-diabetic sulfonylurea and chronic use of 
statins) (reviewed in [274]). Paper IV of this thesis contributes to the literature by 
demonstrating the latter. We found that the combination of IPost with 
pharmacological treatment strategies, here represented by insulin or GSK3β 
inhibition, completely abrogated cardioprotection afforded by the separate treatment 
given alone. Loss of cardioprotection was associated with reduced phosphorylation of 
the pro-survival kinase Akt. The molecular explanation for this observation is still not 
resolved. It does, however, imply that drugs which can modulate Akt, GSK3β or 
other components of the RISK pathway may interfere with IPost mediated 
cardioprotection. Hence, Paper IV provide with suggestions as to why clinical trials 
using IPost have shown varying result. 
5.5 Similarities of anthracycline and ischemia-reperfusion 
mediated cell injury 
The myocardium is generally considered a postmitotic organ, excluding any 
cardiomyocyte turnover in the normal or diseased organ. With the idea of terminally 
differentiated cardiac cells came also the controversy of cardiomyocyte cell death 
[275], as this would eventually lead to the loss of myocardial mass. Today, scientists 
are suggesting that death and regeneration are part of the normal homeostasis of the 
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heart [276], and we know that cell death is involved in both ischemia-reperfusion 
induced injury [125, 277, 278] as well as anthracycline induced cardiotoxicity [279]. 
As described in the introduction, anthracycline mediated cardiotoxicity is believed to 
be distinct from its anti-tumor effect, and is likely to be a result of ROS mediated 
cardiomyocyte damage. Concomitantly, ROS is an important component of ischemia-
reperfusion mediated cell death, and it is therefore relevant to believe that free radical 
injury to the myocardium induced by anthracyclines is similar to that induced by 
ischemia-reperfusion. This is supported by studies demonstrating pharmacological 
cardioprotection against both ischemia-reperfusion injury as well as anthracycline 
induced cardiotoxicity [280, 281]. More interestingly, the most effective experimental 
treatment against ischemia-reperfusion injury, ischemic preconditioning (IPC), are 
also protective against anthracycline (epirubicin) induced cardiotoxicity [282]. 
Conversely, the only approved clinical cardioprotector used to attenuate anthracycline 
mediated cardiotoxicity,  the iron-chelator Dexrazoxane,  are protective against 
ischemia-reperfusion in the ex vivo rat heart [283].  
5.5.1 Increased intracellular  ROS  
Induction of myocardial oxidative stress is the most frequently proposed mechanism 
of anthracycline mediated cardiotoxicity and is described in the cytoplasm, 
mitochondria and sarcoplasmic reticulum [92]. Redox cycling of anthracyclines are 
based on the quinone moiety of the molecule and also their ability to form 
anthracycline-iron complexes [92]. Increased cardiac ROS may injure cell 
membranes and nuclear/mitochondrial DNA leading to changed protein pattern, 
disturbed cell signaling and altered membrane permeability, all culminating in 
increased Ca2+ and apoptosis [109]. It is also of general agreement that increased 
ROS production is involved in myocardial reperfusion injury [150, 284, 285]. Under 
normal conditions, O2−· would be converted to H2O2 by superoxide dismutase. 
However, due to acidosis during ischemia, ferric and ferrous ions released from 
metalloproteins, catalyze the generation of highly reactive hydroxyl radical from both 
O2·− and H2O2 (Fenton reaction) [286]. Paradoxically, we (Paper IV) and others have 
demonstrated that transient and low concentrations of RNS/ROS are required at 
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immediate reperfusion to mediate cardioprotection elicited by ischemic conditioning 
[287-289]. In summary, this thesis illustrates the myriad roles of ROS in a biological 
system. Harmful in one setting (anthracycline induced cardiotoxicity), protective in 
another (ischemic pre- and post-conditioning), and also being necessary for steady 
state signaling. It is obvious that strict regulation is a prerequisite to handle the 
diverse effects of ROS, which involves time-, concentration- and location 
dependencies of different reactive oxygen species.  
5.5.2 Mitochondrial related death/survival pathways 
The effects of oxidative stress on the mitochondrial intrinsic pathway are well 
described, but the involvement of the extrinsic pathway is not yet clarified. Most of 
the ROS induced cellular events described in the above section contribute to cell 
death via apoptosis and necrosis, and is believed to be the primary mechanism of 
anthracycline induced cardiomyopathy [290]. Anthracyclines create Ca2+ flux 
aberration, and hence, increased mitochondrial [Ca2+]. This leads to dissipation of the 
transmembrane potential, mitochondrial swelling and leakage of apoptotic signaling 
molecules, a process involving opening of the mitochondrial permeability transition 
pore (mPTP) [290]. Similarly, (as described in section 1.9.2) the main event linking 
ischemia-reperfusion to cell death is also opening of the mPTP. This is a Ca2+ and 
ROS dependent process [155], inhibited by the acidic environment during ischemia 
while manifested at immediate reperfusion [156, 157]. Attenuation of mPTP opening 
during early reperfusion has gained increased focus, and many cardioprotective 
interventions activate important anti-apoptotic protein kinases such as PI3K-Akt and 
MEK1/2-Erk1/2 (RISK pathway) [153]. Inhibition of mPTP by ischemic conditioning 
involves mitoKATP, PKC and ROS signaling but has previously not been linked to 
insulin and GSK3βi mediated cardioprotection. However, our results in Paper IV 
indicate dependency on PKC and mitoKATP mediated signaling in cardioprotection 
afforded by post-ischemic insulin treatment. It is possible that the administration time 
(pre or post ischemia) explain the opposing findings presented in Paper IV compared 
to others [159, 291].  Recently, inhibition of glycogen synthase kinase 3β (GSK3β) 
has been suggested as the key event linking cardioprotection to inhibition of mPTP 
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[159], and the involvement of Akt phosphorylation and GSK3β inhibition during 
cardioprotection are described in Paper IV. Similarly, anthracyclines seems to inhibit 
Akt phosphorylation and thereby increase the activity of GSK3β [292]. In addition, 
upstream kinase activation of PI3K-Akt with subsequent GSK3β inhibition, are 
protective against anthracycline induced cardiomyocyte apoptosis [292].  
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6. CONCLUSION 
The overall aim of this thesis was to participate in the search for ways to directly or 
indirectly minimize anthracycline mediated cardiotoxicity, and also to reduce the 
amount of ischemia-reperfusion injury. We therefore addressed and answered the 
following specific aims: 
Paper I – Evaluate the influence of cAMP on anthracycline induced apoptosis of 
acute promyelocytic leukemia (APL) cells, since cAMP has been advocated as 
adjuvant to classical APL therapy. 
We found that cAMP abrogates anthracycline induced APL cell death in a PKA type 
I dependent manner. The mechanism was associated with inhibition of pro-apoptotic 
Bad and activation of the acute myeloid leukemia (AML) oncogene CREB. In vitro 
findings were mirrored in vivo (NSG mice with orthotopic NB4 cell leukemia) were 
cAMP induced more rapid APL progression. Together these data suggests that the 
beneficial pro-differentiating effects of cAMP should be weighed against the non-
beneficial pro-survival effect found in this study. 
Paper II - Study the possible cardioprotective effect of Red Palm Oil against 
anthracycline mediated cardiotoxicity 
Red palm oil (RPO) diet supplementation improved cardiac output in hearts from 
animals treated with anthracycline, and also stabilized important antioxidant systems 
such as SOD 1, otherwise decreased by anthracycline treatment. RPO also inhibited 
anthracycline induced stress kinases such as p38 and JNK and up regulated the pro-
survival kinase ERK. 
Paper III - Delineate the cardioprotective effect of corticotropin releasing factor 
(CRF) against ischemia-reperfusion injury 
CRF offered cytoprotection when administered prior to a simulated ischemic insult 
and also reduced infarct size in the ex vivo perfused rat heart. CRF had no protective 
effect when administered at the time of reoxygenation/reperfusion. The protective 
effect of CRF was mediated via CRFR2 and was dependent on PKC and PKA 
signaling.  
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Paper IV - Investigate the combination of known protective therapies against 
ischemia-reperfusion injury 
In this study we found that combination of two pharmacologic reperfusion therapies 
(Insulin or GSK3β-inhibition) did not lead to additive cardioprotection compared to 
the two treatments given alone. However, combining ischemic postconditioning with 
either of the two pharmacologic therapies (Insulin or GSK3β-inhibitor) completely 
abrogated cardioprotection afforded by the separate therapies. This loss of 
cardioprotection was associated with blunted Akt phosphorylation. 
6.1 Concluding Remarks 
This thesis has indirectly (Paper I) and directly (Paper II, III, IV) focused on the 
heart as the primary organ for protection. In Paper I we have participated in the 
search for ways to improve current acute promyelocytic leukemia (APL) treatment. 
The introduction of novel agents to current treatment regimens may reduce, and 
hopefully someday replace, the use of anthracyclines, and thereby alleviate some of 
the cardiotoxic side effects imposed by these agents. In Paper II we demonstrate the 
potential of a natural antioxidant source, the red palm oil (RPO), as a cardioprotector 
against anthracycline induced cardiotoxicity. RPO is also cardioprotective against 
ischemia-reperfusion induced injury and has highly anti-cancer potential due to the 
high level of tocotrienols. Paper III and IV contribute with pharmacologic and 
mechanical treatments to reduce ischemia-reperfusion induced injury. In Paper III 
we show that the novel agent Corticotropin releasing factor (CRF) exerts 
cardioprotection, and demonstrated that the time of administration (pre or post 
ischemia) may give distinct outcome. Finally, Paper IV highlights the importance of 
the finely tuned cellular signaling involved in cardioprotection, as the combination of 
cardioprotective treatments may counteract each other, and address the struggle of 
pre-clinical studies to successfully translate into the clinic.  As a final remark, my 
thesis emphasizes the similarities of anthracycline and ischemia-reperfusion induced 
cell injury. This encourages a more tight collaboration of oncologists and 
cardiologists in the clinic, as well as between pre-clinical researchers from these to 
experimental fields.  
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7. FUTURE PERSPECTIVES 
7.1 Paper I 
cAMP has been suggested as adjuvant to current acute promyelocytic leukemia 
(APL) therapy due to its pro-differentiating effects on ATRA sensitive and in-
sensitive cells. In Paper I we have demonstrated that cAMP attenuate daunorubicin 
induced apoptosis in acute myeloid leukemia (AML) and APL patient cells and the 
APL cell line NB4. The next step would be to combine ATRA with daunorubicine 
(DNR), in the presence and absence of cAMP, to evaluate the net effect of cAMP 
stimulation regarding increased differentiation versus reduced apoptosis.   
Both Bad and CREB phosphorylation are under current investigation as therapeutic 
targets in AML and other malignancies. CREB is an AML proto-oncogene, and 
overexpression is associated with a poor outcome in the patients. Small molecules 
that inhibit binding of CREB to its partners have been identified, and was effective at 
micromolar concentrations, without off-target inhibition of transcriptional machinery 
[293]. Therefore, in vivo experiments with clinical relevant inhibitors of Bad and 
CREB should be tested for their ability to inhibit cAMP induced protection of 
leukemic cells.  
7.2 Paper II 
Paper II demonstrate that diet-supplementation with red palm oil (RPO) during 
chemotherapy protect the rat heart against daunorubicin induced cardiotoxicity, with 
improved aortic output and coronary flow. However, in a follow-up study we would 
lengthen the perfusion protocol in order to achieve a clearer difference between the 
groups regarding the hemodynamic parameters. More importantly, in order to 
investigate if RPO exert any adverse effect in regards to the anti-cancer effect of the 
anthracycline, we would like to evaluate the cardioprotective effects of RPO in a 
leukemia rat model. 
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7.3 Paper III 
Since we strive to perform clinical relevant basic research, we were disappointed 
when corticotropin releasing factor (CRF) did not have any cardioprotective effect 
when administered at reperfusion/reoxygenation. However, there is a possibility that 
CRF could exert protection if applied in another concentration. This further warrants 
a set of dose-response experiments with CRF administration at the moment of 
reperfusion.  
7.4 Paper IV 
Previous studies have shown that insulin has to be present from the onset of 
reperfusion to be cardioprotective, and that cardioprotection is lost when insulin 
administration was delayed 15 min into reperfusion. Similarly, the mechanical 
intervention of IPost has to be performed at early reperfusion. It is likely that the loss 
of protection, when combining IPost with insulin therapy (or GSK3i), is due to 
abrogation of, or interference with, the pro-survival signaling mechanisms activated 
by these treatments when administered separately. Intriguingly, the lack of 
cardioprotection was associated with blunted Akt phosphorylation at early 
reperfusion. In the continuation of this study, we would like to investigate if 
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